Search

Your search keyword '"Seang, S."' showing total 132 results
Start Over Author "Seang, S."
132 results on '"Seang, S."'

4. Oral Glucose Tolerance Testing identifies HIV+ infected women with Diabetes Mellitus (DM) not captured by standard DM definition.

Author

Tien, Phyllis, Seang, S, Lake, JE, Tian, F, Anastos, K, Cohen, MH, and Tien, PC

Abstract

HIV-infected (HIV+) individuals may have differential risk of diabetes mellitus (DM) compared to the general population, and the optimal diagnostic algorithm for DM in HIV+ persons remains unclear. We aimed to assess the utility of oral glucose tolerance t

Published
2016

8. Levels and determinants of breast and cervical cancer screening uptake in HIV‐infected women compared with the general population in France

Author

Tron, L, Lert, F, Spire, B, DraySpira, R, Allègre, T, Mours, P., Riou, J.M., Sordage, M., Chennebault, J. M., Fialaire, P., Rabier, V., Froidure, M., Huguet, D., Leduc, D., Pichancourt, G., Wajsbrot, A., Bourdeaux, C., Foltzer, A., Hoen, B., HustacheMathieu, L., Abgrall, S., Barruet, R., Bouchaud, O., Chabrol, A., Mattioni, S, Mechai, F., Jeantils, V., Bernard, N., Bonnet, F., Hessamfar, M., Lacoste, D., Malvy, D., Mercié, P., Morlat, P., Paccalin, F., Pertusa, M. C., Pistone, T., Receveur, M. C., Vandenhende, M. A., Dupont, C., Freire Maresca, A., Leporrier, J., Rouveix, E., Dargere, S., de la Blanchardière, ., Martin, A., Noyon, V., Verdon, R., Rogeaux, O., Beytout, J., Gourdon, F., Laurichesse, H., Meier, F., Mortier, E., Simonpoli, A. M., Cordier, F., Delacroix, I., Garrait, V., Elharrar, B., Dominguez, S., Lascaux, A. S., Lelièvre, J. D., Levy, Y., Melica, G., Buisson, M., Piroth, L., Waldner, A., Gruat, N., Leprêtre, A., de Truchis, P., Le Du, D, Melchior, J. Cl., Sehouane, R., Troisvallets, D., Blanc, M., BocconGibod, I., Bosseray, A., Brion, J. P., Durand, F., Leclercq, P., Marion, F., Pavese, P., BrottierMancini, E., Faba, L., RoncatoSaberan, M., BollengierStragier, O., Esnault, J. L., LeautezNainville, S., Perré, P., Froguel, E., Nguessan, M., Simon, P., Colardelle, P., Doll, J., GodinCollet, C., RoussinBretagne, S., Delfraissy, J. F., Duracinsky, M., Goujard, C., Peretti, D., Quertainmont, Y., Marionneau, J., Aissi, E., Van Grunderbeeck, N, Denes, E., DucroixRoubertou, S., Genet, C., Weinbreck, P., AugustinNormand, C., Boibieux, A., Cotte, L., Ferry, T., Koffi, J., Miailhes, P., Perpoint, T., Peyramond, D., Schlienger, I., Brunel, J. M., Carbonnel, E., Chiarello, P., Livrozet, J. M., Makhloufi, D., Dhiver, C., Husson, H., Madrid, A., Ravaux, I., de Severac, M.L., Thierry Mieg, M., Tomei, C., Hakoun, S., Moreau, J., Mokhtari, S., Soavi, M. J., Faucher, O., Ménard, A., Orticoni, M., PoizotMartin, I., Soavi, M. J., Atoui, N., Baillat, V., Faucherre, V., Favier, C., Jacquet, J. M., Le Moing, V, Makinson, A., Mansouri, R., Merle, C., Elforzli, N., Allavena, C., Aubry, O., Besnier, M., Billaud, E., Bonnet, B., Bouchez, S., Boutoille, D., Brunet, C., Feuillebois, N., Lefebvre, M., MorineauLe Houssine, P, Mounoury, O., Point, P., Raffi, F., Reliquet, V., Talarmin, J. P., Ceppi, C., Cua, E., Dellamonica, P., De SalvadorGuillouet, Durant, J., Ferrando, S., MondainMiton, V., Perbost, I., Pillet, S., ProuvostKeller, B., Pradier, C., Pugliese, P., Roger, P. M., Rosenthal, E., Sanderson, F., Hocqueloux, L., Niang, M., Prazuck, T., Arsac, P., BarraultAnstett, M.F., Ahouanto, M., Bouvet, E., Castanedo, G., CharloisOu, C., Dia Kotuba, A., EidAntoun, Z., Jestin, C., Jidar, K., Joly, V., KhuongJosses, M. A., Landgraf, N., Landman, R., Lariven, S., Leprêtre, A., Lʼhériteau, F., Machado, M., Matheron, S., Michard, F., Morau, G., Pahlavan, G., Phung, B. C., Prévot, M. H., Rioux, C., Yéni, P., BaniSadr, F., Calboreanu, A., Chakvetadze, E., Salmon, D., Silbermann, B., Batisse, D., Beumont, M., Buisson, M., Castiel, P., Derouineau, J., Eliaszewicz, M., Gonzalez, G., Jayle, D., Karmochkine, M., Kousignian, P., Pavie, J., Pierre, I., Weiss, L., Badsi, E., Bendenoun, M., Cervoni, J., Diemer, M., Durel, A., Rami, A., Sellier, P., AitMohand, H., Amirat, N., Bonmarchand, M., Bourdillon, F., Breton, G., Caby, F., Grivois, J. P., Katlama, C., Kirstetter, M., Paris, L., Pichon, F., Roudière, L., Schneider, L., Samba, M. C., Seang, S., Simon, A., Stitou, H., Tubiana, R., Valantin, M. A., Bollens, D., Bottero, J., Bui, E., Campa, P., Fonquernie, L., Fournier, S., Girard, P. M., Goetschel, A., Guyon, H. F., Lacombe, K., Lallemand, F., Lefebvre, B., Maynard, J. L., Meyohas, M. C., Ouazene, Z., Pacanowski, J., Picard, O., Raguin, G., Roussard, P., Tourneur, M., Tredup, J., Valin, N., Balkan, S., Clavel, F., Colin de Verdière, N, De Castro, N., de Lastours, V., Ferret, S., Gallien, S., Garrait, V., Gérard, L., Goguel, J., Lafaurie, M., LascouxCombe, C., Molina, J. M., Oksenhendler, E., Pavie, J., Pintado, C., Ponscarme, D., Rozenbaum, W., Scemla, A., Bonnard, P., Lassel, L., Lebrette, M. G., Lyavanc, T., Mariot, P., Missonnier, R., Ohayon, M., Pialoux, G., Treilhou, M. P., Vincensini, J. P., Gilquin, J., Hadacek, B., NaitIghil, L., Nguyen, T. H., Pintado, C., Sobel, A., Viard, J. P., Zak Dit Zbar, O., Aumaître, H., Eden, A., Ferreyra, M., Lopez, F., Medus, M., Neuville, S., Saada, M., Blum, L., Perfezou, P., Arvieux, C., Chapplain, J. M., Revest, M., Souala, F., Tattevin, P., Bord, S., BorsaLebas, F., Caron, F., Chapuzet, C., Debab, Y., Gueit, I., Etienne, M., Fartoukh, C., Feltgen, K., Joly, C., RobadayVoisin, S., Suel, P., Khuong, M. A., Krausse, J., Poupard, M., Tran Van, G., Cazorla, C., Daoud, F., Fascia, P., Frésard, A., Guglielminotti, C., Lucht, F., BernardHenry, C., Cheneau, C., Lang, J. M., de Mautort, E., Partisani, M., Priester, M., Rey, D., Majerholc, C., Zucman, D., Assi, A., Lafeuillade, A., de Jaureguiberry, J. P., Gisserot, O., Aquilina, C., Prevoteau du Clary, F., Alvarez, M., Chauveau, M., Cuzin, L., Delobel, P., Garipuy, D., Labau, E., Marchou, B., Massip, P., Mularczyk, M., Obadia, M., Ajana, F., Allienne, C., Baclet, V., de la Tribonnière, X, Huleux, T., Melliez, H., Meybeck, A., Riff, B., Valette, M., Viget, N., Bastides, F., Bernard, L., Gras, G., Guadagnin, P., May, T., Rabaud, C., Dos Santos, A, P oinsignon, Y., Derradji, O., Escaut, L., Teicher, E., Vittecoq, D., Bantsima, J., CarauxPaz, P., and Patey, O.

Published
2017
Full Text
View/download PDF

10. Effect of systematic tuberculosis detection on mortality in young children with severe pneumonia in countries with high incidence of tuberculosis: a stepped-wedge cluster-randomised trial

Author

Marcy, O, Wobudeya, E, Font, H, Vessière, A, Chabala, C, Khosa, C, Taguebue, J-V, Moh, R, Mwanga-Amumpaire, J, Lounnas, M, Mulenga, V, Mavale, S, Chilundo, J, Rego, D, Nduna, B, Shankalala, P, Chirwa, U, De Lauzanne, A, Dim, B, Tiogouo Ngouana, E, Folquet Amorrissani, M, Cisse, L, Amon Tanoh Dick, F, Komena, EA, Kwedi Nolna, S, Businge, G, Natukunda, N, Cumbe, S, Mbekeka, P, Kim, A, Kheang, C, Pol, S, Maleche-Obimbo, E, Seddon, JA, Mao, TE, Graham, SM, Delacourt, C, Borand, L, Bonnet, M, Serre, A, Badrichani, A, Razafimanantsoa, M, Poublan, J, Roucher, C, Occelli, E, Beuscart, A, Charpin, A, Habiyambere, G, Mesnier, S, Balestre, E, Bhatta, B, Maillard, A-L, Orne-Gliemann, J, Baillet, E, Koskas, N, D'Elbée, M, Gabillard, D, Huyen, M, Espérou, H, Couffin-Cadiergues, S, Kuppers, A, Hamze, B, BORAND, L, de LAUZANNE, A, DIM, B, Keang, C, PRING, L, YIN, S, SARITH, C, PHAN, C, NHEUONG, S, LY, S, KAING, S, SRENG, V, LUN, E, SAY, L, SUOM, S, FERHY, R, SO, D, BORN, S, PAL, S, NANG, B, MAO, TE, KIM, A, Srey, V, Kan, P, Hout, L, Ith, S, Oum, S, Sau, S, Ho, KH, Kith, D, Nuch, N, Horm, CL, Sophon, C, Roeungdeth, B, MENG, C, RITH, R, PHY, S, SOR, C, SAO, V, KHAT, S, MAK, B, UY, A, KHAY, S, SOM, K, HACH, R, SOK, H, KUON, S, HENG, S, SENG, A, NIM, S, PAN, R, KIM, S, SREY LEAP, K, NET, B, NOUN, V, LAY, D, MANY, C, Seng, S, Ly, V, So, S, Oun, S, CHEY, S, CHHEA, R, BAONG, L, THOUNG, V, KHEANG, C, BY, B, Nguon, V, MEACH, E, Tek, S, Ngeav, S, Lun, T, HEM, D, CHUT, N, SARIK, S, NANG, H, MEACH, M, SRENG, S, SAR, D, KIN, R, ROS, P, DORN, C, KAK, C, Sambath, SL, Son, L, Bin, L, Pengong, E, Khutsorn, S, Seang, S, Soun, V, Vong, V, Khoeung, C, Um, P, Bou, S, Song Pich, S, Nim, P, Khat, S, Ban Si, N, Ream, S, Ing, S, Chann, P, Ngeth, S, Sun, M, Chhoeung, S, Sean, S, Prak, R, Amboua Schouame Onambele, A, Hycenth, N, Melingui, B, Nkembe Medounmga, A, Hougnang Tatmi, L, Etemgoua, N, Kouesso, V, Bugin, J, Nzedjom, C, Ngoya, R, Eyike, J, Loudjom, E, Lonsti, R, Dang, L, Bintar, E, Njayong, C, Ngonsoa O, C, Ndzeukap, I, Dzoyem, P, Dzokou, C, Dindo, B, Aka Bony, R, Kouadio, C, Danho, S, Goli, M, Folquet, M, Itchy, MV, Sidibé, A, Cissé, L, Ouattara, J, Konaté, M, Amon-Tanoh Dick, F, Cardena, M, Adonis-Koffi, L, Eugenie, D, Kouamé, F, Menan, H, Inwoley, A, Ouassa, T, Nguessan, MS, Manhiça, E, Zitha, A, Chiúle, V, Muxanga, E, Gune, I, Lima, Y, Ribeiro, J, Maxanguana, F, Morais, N, Manhiça, J, Give, J, Atumane, J, Lucas, G, Thai, A, Chave, A, Guambe, L, Issa, F, Carneiro, R, Pene, N, Florindo, N, Machel, D, Cumbane, C, Mendes, H, Kitungwa, M, Muianga, V, Tamele, H, Sulude, A, Mabota, R, Comandante, H, Massangaie, A, Businge, GB, Namulinda, F, Sserunjogi, R, Nassozi, R, Barungi, C, Aanyu, H, Muwonge, D, Kagoya, E, Aciparu, S, Chemutai, S, Ntambi, S, Wasswa, A, Nangozi, J, Tagoola, A, Kenneth, S, Lubega, JP, Nassali, A, Tagobera, J, Agwang, C, Kalembe, F, Ajambo, A, Aguti, E, Kasibante, S, Matende, H, Odongo, IO, Mwanga Amumpaire, J, Ngabirano, G, Kakwenza, P, Nuwamanya, S, Nyangoma, M, Nabbuto, J, Abok, F, Arinaitwe, R, Birungi, D, Mwesigwa, E, Atwine, D, Mbega, H, Orikiriza, P, Taremwa, I, Turyashemererwa, E, Derrick, H, Nyehangane, D, Kaitano, R, Logoose, S, Businge, S, Ntambi, C, Mugabi, J, Mzee, J, Besigye, J, Kanzira, S, Turyatemba, P, Twebaze, F, Hambulo, C, Kapotwe, V, Ngambi, M, Kasakwa, K, Kapula, C, Zulu, S, Nawakwi, G, Siasulingana, T, Chilonga, J, Chimbini, M, Chilanga, M, Inambao, M, Mwambazi, M, Halende, B, Mumba, W, Mankunshe, E, Silavwe, M, Chakopo, M, Moono, R, Marcy, O, Wobudeya, E, Font, H, Vessière, A, Chabala, C, Khosa, C, Taguebue, J-V, Moh, R, Mwanga-Amumpaire, J, Lounnas, M, Mulenga, V, Mavale, S, Chilundo, J, Rego, D, Nduna, B, Shankalala, P, Chirwa, U, De Lauzanne, A, Dim, B, Tiogouo Ngouana, E, Folquet Amorrissani, M, Cisse, L, Amon Tanoh Dick, F, Komena, EA, Kwedi Nolna, S, Businge, G, Natukunda, N, Cumbe, S, Mbekeka, P, Kim, A, Kheang, C, Pol, S, Maleche-Obimbo, E, Seddon, JA, Mao, TE, Graham, SM, Delacourt, C, Borand, L, Bonnet, M, Serre, A, Badrichani, A, Razafimanantsoa, M, Poublan, J, Roucher, C, Occelli, E, Beuscart, A, Charpin, A, Habiyambere, G, Mesnier, S, Balestre, E, Bhatta, B, Maillard, A-L, Orne-Gliemann, J, Baillet, E, Koskas, N, D'Elbée, M, Gabillard, D, Huyen, M, Espérou, H, Couffin-Cadiergues, S, Kuppers, A, Hamze, B, BORAND, L, de LAUZANNE, A, DIM, B, Keang, C, PRING, L, YIN, S, SARITH, C, PHAN, C, NHEUONG, S, LY, S, KAING, S, SRENG, V, LUN, E, SAY, L, SUOM, S, FERHY, R, SO, D, BORN, S, PAL, S, NANG, B, MAO, TE, KIM, A, Srey, V, Kan, P, Hout, L, Ith, S, Oum, S, Sau, S, Ho, KH, Kith, D, Nuch, N, Horm, CL, Sophon, C, Roeungdeth, B, MENG, C, RITH, R, PHY, S, SOR, C, SAO, V, KHAT, S, MAK, B, UY, A, KHAY, S, SOM, K, HACH, R, SOK, H, KUON, S, HENG, S, SENG, A, NIM, S, PAN, R, KIM, S, SREY LEAP, K, NET, B, NOUN, V, LAY, D, MANY, C, Seng, S, Ly, V, So, S, Oun, S, CHEY, S, CHHEA, R, BAONG, L, THOUNG, V, KHEANG, C, BY, B, Nguon, V, MEACH, E, Tek, S, Ngeav, S, Lun, T, HEM, D, CHUT, N, SARIK, S, NANG, H, MEACH, M, SRENG, S, SAR, D, KIN, R, ROS, P, DORN, C, KAK, C, Sambath, SL, Son, L, Bin, L, Pengong, E, Khutsorn, S, Seang, S, Soun, V, Vong, V, Khoeung, C, Um, P, Bou, S, Song Pich, S, Nim, P, Khat, S, Ban Si, N, Ream, S, Ing, S, Chann, P, Ngeth, S, Sun, M, Chhoeung, S, Sean, S, Prak, R, Amboua Schouame Onambele, A, Hycenth, N, Melingui, B, Nkembe Medounmga, A, Hougnang Tatmi, L, Etemgoua, N, Kouesso, V, Bugin, J, Nzedjom, C, Ngoya, R, Eyike, J, Loudjom, E, Lonsti, R, Dang, L, Bintar, E, Njayong, C, Ngonsoa O, C, Ndzeukap, I, Dzoyem, P, Dzokou, C, Dindo, B, Aka Bony, R, Kouadio, C, Danho, S, Goli, M, Folquet, M, Itchy, MV, Sidibé, A, Cissé, L, Ouattara, J, Konaté, M, Amon-Tanoh Dick, F, Cardena, M, Adonis-Koffi, L, Eugenie, D, Kouamé, F, Menan, H, Inwoley, A, Ouassa, T, Nguessan, MS, Manhiça, E, Zitha, A, Chiúle, V, Muxanga, E, Gune, I, Lima, Y, Ribeiro, J, Maxanguana, F, Morais, N, Manhiça, J, Give, J, Atumane, J, Lucas, G, Thai, A, Chave, A, Guambe, L, Issa, F, Carneiro, R, Pene, N, Florindo, N, Machel, D, Cumbane, C, Mendes, H, Kitungwa, M, Muianga, V, Tamele, H, Sulude, A, Mabota, R, Comandante, H, Massangaie, A, Businge, GB, Namulinda, F, Sserunjogi, R, Nassozi, R, Barungi, C, Aanyu, H, Muwonge, D, Kagoya, E, Aciparu, S, Chemutai, S, Ntambi, S, Wasswa, A, Nangozi, J, Tagoola, A, Kenneth, S, Lubega, JP, Nassali, A, Tagobera, J, Agwang, C, Kalembe, F, Ajambo, A, Aguti, E, Kasibante, S, Matende, H, Odongo, IO, Mwanga Amumpaire, J, Ngabirano, G, Kakwenza, P, Nuwamanya, S, Nyangoma, M, Nabbuto, J, Abok, F, Arinaitwe, R, Birungi, D, Mwesigwa, E, Atwine, D, Mbega, H, Orikiriza, P, Taremwa, I, Turyashemererwa, E, Derrick, H, Nyehangane, D, Kaitano, R, Logoose, S, Businge, S, Ntambi, C, Mugabi, J, Mzee, J, Besigye, J, Kanzira, S, Turyatemba, P, Twebaze, F, Hambulo, C, Kapotwe, V, Ngambi, M, Kasakwa, K, Kapula, C, Zulu, S, Nawakwi, G, Siasulingana, T, Chilonga, J, Chimbini, M, Chilanga, M, Inambao, M, Mwambazi, M, Halende, B, Mumba, W, Mankunshe, E, Silavwe, M, Chakopo, M, and Moono, R

Abstract

Background: Tuberculosis diagnosis might be delayed or missed in children with severe pneumonia because this diagnosis is usually only considered in cases of prolonged symptoms or antibiotic failure. Systematic tuberculosis detection at hospital admission could increase case detection and reduce mortality. Methods: We did a stepped-wedge cluster-randomised trial in 16 hospitals from six countries (Cambodia, Cameroon, Côte d'Ivoire, Mozambique, Uganda, and Zambia) with high incidence of tuberculosis. Children younger than 5 years with WHO-defined severe pneumonia received either the standard of care (control group) or standard of care plus Xpert MTB/RIF Ultra (Xpert Ultra; Cepheid, Sunnyvale, CA, USA) on nasopharyngeal aspirate and stool samples (intervention group). Clusters (hospitals) were progressively switched from control to intervention at 5-week intervals, using a computer-generated random sequence, stratified on incidence rate of tuberculosis at country level, and masked to teams until 5 weeks before switch. We assessed the effect of the intervention on primary (12-week all-cause mortality) and secondary (including tuberculosis diagnosis) outcomes, using generalised linear mixed models. The primary analysis was by intention to treat. We described outcomes in children with severe acute malnutrition in a post hoc analysis. This study is registered with ClinicalTrials.gov (NCT03831906) and the Pan African Clinical Trial Registry (PACTR202101615120643). Findings: From March 21, 2019, to March 30, 2021, we enrolled 1401 children in the control group and 1169 children in the intervention group. In the intervention group, 1140 (97·5%) children had nasopharyngeal aspirates and 942 (80·6%) had their stool collected; 24 (2·1%) had positive Xpert Ultra. At 12 weeks, 110 (7·9%) children in the control group and 91 (7·8%) children in the intervention group had died (adjusted odds ratio [OR] 0·986, 95% CI 0·597–1·630, p=0·957), and 74 (5·3%) children in the control group

Published
2022

11. Combined ART started during acute HIV infection protects central memory CD4+ T cells and can induce remission

Author

Chéret, Antoine, Bacchus-Souffan, Charline, Avettand-Fenoël, Veronique, Mélard, Adeline, Nembot, Georges, Blanc, Catherine, Samri, Assia, Sáez-Cirión, Asier, Hocqueloux, Laurent, Lascoux-Combe, Caroline, Allavena, Clotilde, Goujard, Cécile, Valantin, Marc Antoine, Leplatois, Anne, Meyer, Laurence, Rouzioux, Christine, Autran, Brigitte, Hoen, B., Bourdeaux, C., Delfraissy, J. F., Goujard, C., Amri, I., Fourn, E., Quertainmont, Y., Môle, M., Rami, A., Durel, A., Diemer, M., Parrinello, M., Allègre, T., Lafeuillade, A., Hittinger, G., Lambry, V., Carrerre, M., Philip, G., Duvivier, C., Consigny, P. H., Charlier, C., Shoai, M., Touam, F., Pialoux, G., Slama, L., LʼYavanc, T., Mathurin, P., Adda, A., Berrebi, V., Salmon, D., Chakvetadze, E., Tassadit, T., Ousseima, E., Pietri, M. P., Levy, Y., Lascaux, A. S., Lelievre, J. D., Giovanna, M., Dominguez, S., Dumont, C., Katlama, C., Valentin, M. A., Seang, S., Schneider, L., Kiorza, N., Chermak, A., Ben Abdallah, S., Simon, A., Pichon, F., Pauchard, M., Molina, J. M., Lascoux, C., Ponscarme, D., Colin De Verdiere, N., Scemla, A., De Castro, N., Rachline, A., Garrait, V., Rozenbaum, W., Ferret, S., Balkan, S., Clavel, F., Tourdjman, M., Lafaurie, M., Aslan, A., Goguel, J., Thierry, S. M., De Lastours, V., Gallien, S., Pavie, J., Delgado, J., Mededji, C., Veron, R., Abel, S., Pierre-François, S., Baringhton, C., Chennebault, J. M., Vandamme, Y. M., Fialaire, P., Rehaiem, S., Rabier, V., Abgueguen, P., Morlat, P., Vandenhende, M. A., Bernard, N., Lacoste, D., Michaux, C., Paccalin, F., Receveur, M. C., Caldato, S., Delaune, J., Ragnaud, J. M., Neau, D., Lacaze-Buzy, L., Livrozet, J. M., Jeanblanc, F., Makhloufi, D., Brunel Dalmas, F., Jourdain, J. J., Chiarello, P., Yeni, P., Phung, B., Rioux, C., Godard, C., Louni, F., El Alami Talbi, N., Catalano, G., Guiroy, F., Reynes, J., Jacquet, J. M., Fauchere, V., Merle, C., Lemoine, V., Loriette, M., Morquin, D., Makinson, A., Atoui, N., Tramoni, C., Raffi, F., Allavena, C., Bonnet, B., Bouchez, S., Feuillebois, N., Brunet-François, C., Reliquet, V., Mounoury, O., Morineau-Le-Houssine, P., Billaud, E., Brosseau, D., Hüe, H., Dellamonica, P., Vassallo, M., Leplatois, A., Durant, J., Naqvi, A., Joulié, A., Souala, F., Michelet, C., Arvieux, C., Tattevin, P., Leroy, H., Revest, M., Fily, F., Chapplain, J. M., Ratajczak, C. M., Gras, G., Bernard, L., Dailloux, J. F., Laplantine, V., Cuzin, L., Marchou, B., Larrigue, S., Chauveau, M., Balsarin, F., Obadia, M., Chéret, A., Bonne, S., Huleux, T., Ajana, F., Alcaraz, I., Baclet, V., Melliez, H., Viget, N., De La Tribonniere, X., Aissi, E., Poissy, J., Ravaux, I., Vallon, A., Varan, M., May, T., Letranchant, L., Burty, C., Briaud, A., Wassoumbou, S., Stenzel, M., Bouillon, M. P., Debab, Y., Caron, F., Gueit, I., Chapuzet, C., Borsa Lebas, F., Etienne, M., Miailhes, P., Perpoint, T., Senechal, A., Schlienger, I., Cotte, L., Augustin Normand, C., Boibieux, A., Ferry, T., Corsini, N., Braun, E., Lippran, J., Biron, F., Chidiac, C., Pailhes, S., Lipman, J., Braun, E., Koffi, J., Thoirain, V., Brochier, C., Greder Belan, A., Therby, A., Monnier, S., Ruquet, M., Garrait, V., Richier, L., Prevoteau Du Clary, F., Philibert, P., Chapus, C., Cabié, A., and Abel, S.

Published
2015
Full Text
View/download PDF

12. HIV-1 subtype B-infected MSM may have driven the spread of transmitted resistant strains in France in 2007–12: impact on susceptibility to first-line strategies

Author

Frange, Pierre, Assoumou, Lambert, Descamps, Diane, Chéret, Antoine, Goujard, Cécile, Tran, Laurent, Gousset, Marine, Avettand-Fenoël, Veronique, Bocket, Laurence, Fafi-Kremer, Samira, Guinard, Jerome, Morand-Joubert, Laurence, Nicot, Florence, Plantier, Jean-Christophe, Rogez, Sylvie, Wirden, Marc, Rouzioux, Christine, Meyer, Laurence, Chaix, Marie-Laure, Abel, S., Abraham, B., Allegre, T., Antoniotti, A., Armero, R., Audhuy, B., Aumaitre, H., Beaucaire, G., Beck-Wirth, G., Berger, J.L., Bernard, L., Beuscart, C., Bodard, L., Bouchaud, O., Boué, F., Cabane, J.-P., Cabie, A., Champagne, H., Cheneau, C., Chennebault, J.-M., Cheret, A., Christian, B., Compagnucci, A., Daneluzzi, V., Debab, Y., Dellamonica, P., Delfraissy, J.-F., Devidas, A., Diab, G., Doll, J., Drobacheff-Thebaut, M.C., Durel, A., Duvivier, C., Esnault, J.-L., Faba, L., Froguel, E., Garipuy, D., Garrait, V., Geffray, L., Genet, C., Genet, P., Gerard, L., Ghosn, J., Girard, J-.J., Girard, P.-M., Godin-Collet, C., Hochedez, P., Hoen, B., Houlbert, D., Jacomet, C., Jeantils, V., Jidar, K., Katlama, C., Klement, E., Lafeuillade, A., Lascoux, C., Launay, V., Lepretre, A., Levy, Y., Makhloufi, D., Malbec, D., Martha, B., May, T., Merrien, D., Miailhes, P., Miodovski, C., Molina, J.-M., Morlat, P., Mortier, E., Neau, D., Obadia, M., Patey, O., Pellegrin, J.-L., Perronne, V., Philibert, P., Pialoux, G., Pichancourt, G., Piroth, L., Poinsignon, Y., Poizot-Martin, I., Prazuck, T., Prendki, V., du Clary, F. Preveteau, Quinsat, D., Raffi, F., Regnier, A., Reynes, J., Rosenthal, E., Rouveix, E., Salmon, D., Salanville, F., Schmitt, J.-L., Simon-Coutellier, A., Sotto, A., Souala, F., Stein, A., Timsit, F., de Truchis, P., Uludag, A., Vaillant, O., Verdon, R., Verlesch-Langlin, A., Viard, J.-P., Vittecoq, D., Weiss, L., Yéni, P., Zucman, D., Allavena, C., Allegre, T., Amri, I., Autran, B., Bacchus, C., Blanc, C., Bonne, S., Bonnet, B., Bouchez, S., Charlier, C., Consigny, P.-H., Duvivier, C., Fourn, E., Guiroy, F., Huleux, T., Katlama, C., Lascoux-Combe, C., Leplatois, A., Lyavanc, T., Molina, J.-M., Naqvi, A., Nembot, G., Quertainmont, Y., Raffi, F., Samri, A., Schneider, L., Seang, S., Seksik, B.C.P., Shoai-Tehrani, M., Slama, L., Valentin, M.-A., Yazdanpanah, Y., Alloui, C., Amiel, C., André, P., André-Garnier, E., Anies, G., Barin, F., Bellecave, P., Bettinger, D., Bouvier-Alias, M., Brun-Vézinet, F., Calmy, A., Calvez, V., Caveng, W., Chaillon, A., Chapalay, S., Charpentier, C., Costagliola, D., Cottalorda, J., Delamare, C., Delaugerre, C., Dina, J., Santos, G. Dos, Férré, V., Flandre, P., Fleury, H., Fourati, S., Gaille, C., Giraudeau, G., Guigon, A., Haim-Boukobza, S., Lagier, E., Le Guillou-Guillemette, H., Henquell, C., Izopet, J., Lambert-Niclot, S., Leroux, M., Maillard, A., Malet, I., Marcelin, A.-G., Marque-Juillet, S., Masquelier, B., Mirand, A., Morand, P., Montes, B., Mouna, L., Noel, C., Pallier, C., Peytavin, G., Pinson-Recordon, P., Poveda, J.D., Raymond, S., Reigadas, S., Roques, A.-M., de Rougemont, A., Roussel, C., Schmitt, M.-P., Schneider, V., Schvoerer, E., Signori-Schmuck, A., Soulié, C., Tamalet, C., Tardy, J.C., Trabaud, M.-A., Vabret, A., Vallet, S., and Yerly, S.

Published
2015
Full Text
View/download PDF

13. Une série de 21 cas d’infections causées par Trichophyton mentagrophytes génotype VII diagnostiquées chez des hommes ayant des relations sexuelles avec des hommes

Author

Jabet, A., Dellière, S., Seang, S., Barete, S., Nouchi, A., Brin, C., Bozonnat, A., Fekkar, A., Siguier, M., Chiarabini, T., Chasset, F., Canestri, A., Hennequin, C., Teboul, A., Hickman, G., Hamane, S., Benderdouche, M., Makhloufi, S., Piarroux, R., Normand, A.C., and Monsel, G.

Published
2023
Full Text
View/download PDF

15. Microelimination or Not? The Changing Epidemiology of Human Immunodeficiency Virus-Hepatitis C Virus Coinfection in France 2012-2018

Author

Pradat, Pierre, Chirouze, C, Drobacheff-Thiébaut, C, Foltzer, A, Bouiller, K, Hustache-Mathieu, L, Lepiller, Q, Bozon, F, Babre, O, Brunel, A, Muret, P, Chevalier, E, Jacomet, C, Laurichesse, H, LESENS, O, Vidal, M, Mrozek, N, Aumeran, C, Baud, O, Corbin, V, Goncalvez, E, Mirand, A, brebion, A, Henquell, C, Lamaury, I, Fabre, I, Curlier, E, Ouissa, R, Herrmann-Storck, C, Tressieres, B, Receveur, M, Boulard, F, Daniel, C, CLAVEL, C, Roger, P, Markowicz, S, Chellum Rungen, N, Merrien, D, Perré, P, Guimard, T, Bollangier, O, Leautez, S, Morrier, M, Laine, L, Boucher, D, Point, P, Cotte, Laurent, Ader, F, Becker, A, Boibieux, A, Brochier, C, Brunel-Dalmas, F, Cannesson, O, Chiarello, P, Chidiac, C, Degroodt, S, FERRY, T, Godinot, M, Livrozet, J, Makhloufi, D, Miailhes, P, Perpoint, T, Perry, M, Pouderoux, C, Roux, Stéphane, Triffault-Fillit, C, Valour, F, Charre, C, Icard, V, Tardy, J, Trabaud, M, Ravaux, I, Ménard, A, Belkhir, A, Colson, P, Dhiver, C, Madrid, A, Martin-Degioanni, M, Meddeb, L, Mokhtari, M, Motte, A, Raoux, A, Toméi, C, Tissot-Dupont, H, Poizot-Martin, Isabelle, Brégigeon, S, Zaegel-Faucher, O, Obry-Roguet, V, Laroche, H, Orticoni, M, Soavi, M, Ressiot, E, Ducassou, M, Jaquet, I, Galie, S, Colson, H, Ritleng, A, Ivanova, A, Debreux, C, Lions, C, Rojas-Rojas, T, Cabié, André, Abel, S, Bavay, J, Bigeard, B, Cabras, O, Cuzin, L, Dupin de Majoubert, R, Fagour, L, Guitteaud, K, Marquise, A, Najioullah, F, Pierre-François, S, Pasquier, J, Richard, P, Rome, K, Turmel, J, Varache, C, Atoui, N, Bistoquet, M, Delaporte, E, Le Moing, V, Makinson, A, Meftah, N, Merle de Boever, C, Montes, B, Montoya Ferrer, A, Tuaillon, E, Reynes, J, Lefèvre, B, Jeanmaire, E, Hénard, S, Frentiu, E, Charmillon, A, Legoff, A, Tissot, N, André, M, Boyer, L, Bouillon, M, Delestan, M, Goehringer, F, Bevilacqua, S, Rabaud, C, May, T, Raffi, F, Allavena, C, Aubry, O, Billaud, E, Biron, C, Bonnet, B, Bouchez, S, Boutoille, D, Brunet-Cartier, C, Deschanvres, C, Gaborit, B, Grégoire, A, Grégoire, M, Grossi, O, Guéry, R, Lefebvre, Maeva, Le Turnier, P, Lecomte, R, Morineau, P, Reliquet, V, Sécher, S, Cavellec, M, Paredes, E, Soria, A, Ferré, V, André-Garnier, E, Rodallec, A, Pugliese, Pascal, Breaud, S, Ceppi, C, Chirio, D, Cua, E, Dellamonica, P, Demonchy, E, De Monte, A, Durant, J, Etienne, C, Ferrando, S, Garraffo, R, Michelangeli, C, Mondain, V, Naqvi, A, Oran, N, Perbost, I, Carles, M, Klotz, C, Maka, A, Pradier, C, Prouvost-Keller, B, Risso, K, Rio, V, Rosenthal, E, Touitou, I, Wehrlen-Pugliese, S, Zouzou, G, Hocqueloux, Laurent, Prazuck, T, Gubavu, C, Sève, A, Giaché, S, Rzepecki, V, Colin, M, Boulard, C, Thomas, G, Cheret, A, Goujard, C, Quertainmont, Y, Teicher, E, Lerolle, N, Jaureguiberry, S, Colarino, R, Deradji, O, Castro, A, Barrail-Tran, A, Yazdanpanah, Y, Landman, R, Joly, V, Ghosn, J, Rioux, C, Lariven, S, gervais, a, Lescure, F, Matheron, S, Louni, F, Julia, Z, Le Gac, S, Charpentier, c, Descamps, D, Peytavin, G, Duvivier, C, Aguilar, C, Alby-Laurent, F, Amazzough, K, Benabdelmoumen, G, Bossi, P, Cessot, G, Charlier, C, Consigny, P, Jidar, K, Lafont, E, Lanternier, F, Leporrier, J, Lortholary, O, Louisin, C, Lourenco, J, Parize, P, Pilmis, B, Rouzaud, C, Touam, F, Valantin, M, Tubiana, R, Agher, R, Seang, S, Schneider, L, PaLich, R, Blanc, C, Katlama, C, Bani-Sadr, Firouze, Berger, J, N’Guyen, Y, Lambert, D, Kmiec, I, Hentzien, M, Brunet, A, Romaru, J, Marty, H, Brodard, V, Arvieux, C, Tattevin, P, Revest, M, Souala, F, Baldeyrou, M, Patrat-Delon, S, Chapplain, J, Benezit, F, Dupont, M, Poinot, M, MAILLARD, A, Pronier, C, Lemaitre, F, Morlat, C, Poisson-Vannier, M, Jovelin, T, Sinteff, J, Gagneux-Brunon, A, Botelho-Nevers, E, Frésard, A, Ronat, V, Lucht, F, Rey, David, Fischer, P, Partisani, M, Cheneau, C, Priester, M, Mélounou, C, Bernard-Henry, C, de Mautort, E, Fafi-Kremer, S, Delobel, P, Alvarez, M, Biezunski, N, Debard, A, Delpierre, C, Gaube, G, Lansalot, P, Lelièvre, L, Marcel, M, Martin-Blondel, G, Piffaut, M, Porte, L, Saune, K, Robineau, O, Ajana, F, Aïssi, E, Alcaraz, I, Alidjinou, E, Baclet, V, Bocket, L, Boucher, A, Digumber, M, Huleux, Thomas, Lafon-Desmurs, B, Meybeck, A, Pradier, M, Tetart, M, Thill, P, Viget, N, Valette, M, Pathogenesis and Control of Chronic and Emerging Infections (PCCEI), Université des Antilles (UA)-Etablissement français du don du sang [Montpellier]-Université de Montpellier (UM)-Institut National de la Santé et de la Recherche Médicale (INSERM), Hôpital de la Croix-Rousse [CHU - HCL], Hospices Civils de Lyon (HCL), Centre Hospitalier Régional d'Orléans (CHRO), Centre d’Investigation Clinique de Nantes (CIC Nantes), Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre hospitalier universitaire de Nantes (CHU Nantes), Hôpital universitaire Robert Debré [Reims], Centre Hospitalier Gustave Dron [Tourcoing], Hôpital Sainte-Marguerite [CHU - APHM] (Hôpitaux Sud ), Aix Marseille Université (AMU), Sciences Economiques et Sociales de la Santé & Traitement de l'Information Médicale (SESSTIM - U1252 INSERM - Aix Marseille Univ - UMR 259 IRD), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Hospitalier Universitaire de Nice (CHU Nice), Hôpital l'Archet, Les Hôpitaux Universitaires de Strasbourg (HUS), Centre Hospitalier Universitaire de Martinique [Fort-de-France, Martinique], Université des Antilles (UA), Centre d'Investigation Clinique Antilles-Guyane (CIC - Antilles Guyane), Université des Antilles et de la Guyane (UAG)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pointe-à-Pitre/Abymes [Guadeloupe] -CHU de Fort de France-Centre Hospitalier Andrée Rosemon [Cayenne, Guyane Française], Dat’AIDS Study Group Besançon: C. Chirouze, C. Drobacheff-Thiébaut, A. Foltzer, K. Bouiller, L. Hustache- Mathieu, Q. Lepiller, F. Bozon, O. Babre, AS. Brunel, P. Muret, E. Chevalier. Clermont-Ferrand: C. Jacomet, H. Laurichesse, O. Lesens, M. Vidal, N. Mrozek, C. Aumeran, O. Baud, V. Corbin, E. Goncalvez, A Mirand, A brebion, C Henquell. Guadeloupe: I. Lamaury, I. Fabre, E. Curlier, R. Ouissa, C. Herrmann-Storck, B. Tressieres, MC. Receveur, F. Boulard, C. Daniel, C. Clavel, PM. Roger, S. Markowicz, N. Chellum Rungen. La Roche sur Yon: D. Merrien, P. Perré, T. Guimard, O. Bollangier, S. Leautez, M. Morrier, L. Laine, D. Boucher, P. Point. Lyon: L. Cotte, F. Ader, A. Becker, A. Boibieux, C. Brochier F, Brunel-Dalmas, O. Cannesson, P. Chiarello, C. Chidiac, S. Degroodt, T. Ferry, M. Godinot, J.M. Livrozet, D. Makhloufi, P. Miailhes, T. Perpoint, M. Perry, C. Pouderoux, S. Roux, C. Triffault-Fillit, F. Valour, C. Charre, V. Icard, J.C. Tardy, M.A. Trabaud. Marseille IHU Méditerrannée: I. Ravaux, A. Ménard, AY. Belkhir, P. Colson, C. Dhiver, A. Madrid, M. Martin-Degioanni, L. Meddeb, M. Mokhtari, A. Motte, A. Raoux, C. Toméi, H. Tissot-Dupont. Marseille Ste Marguerite: I. Poizot-Martin, S. Brégigeon, O. Zaegel-Faucher, V. Obry-Roguet, H Laroche, M. Orticoni, M.J. Soavi, E. Ressiot, M.J. Ducassou, I. Jaquet, S. Galie, H. Colson, A.S. Ritleng, A. Ivanova, C. Debreux, C. Lions, T Rojas-Rojas. Martinique: A. Cabié, S. Abel, J. Bavay, B. Bigeard, O. Cabras, L. Cuzin, R. Dupin de Majoubert, L. Fagour, K. Guitteaud, A. Marquise, F. Najioullah, S. Pierre-François, J. Pasquier, P. Richard, K. Rome, JM Turmel, C. Varache. Montpellier: N. Atoui, M. Bistoquet, E Delaporte, V. Le Moing, A. Makinson, N. Meftah, C. Merle de Boever, B. Montes, A. Montoya Ferrer, E. Tuaillon, J. Reynes. Nancy: B. Lefèvre, E. Jeanmaire, S. Hénard, E. Frentiu, A. Charmillon, A. Legoff, N. Tissot, M. André, L. Boyer, MP. Bouillon, M. Delestan, F. Goehringer, S. Bevilacqua, C. Rabaud, T. May. Nantes: F. Raffi, C. Allavena, O. Aubry, E. Billaud, C. Biron, B. Bonnet, S. Bouchez, D. Boutoille, C. Brunet-Cartier, C. Deschanvres, B.J. Gaborit, A. Grégoire, M. Grégoire, O. Grossi, R. Guéry, T. Jovelin, M. Lefebvre, P. Le Turnier, R. Lecomte, P. Morineau, V. Reliquet, S. Sécher, M. Cavellec, E. Paredes, A. Soria, V. Ferré, E. André-Garnier, A. Rodallec. Nice: P. Pugliese, S. Breaud, C. Ceppi, D. Chirio, E. Cua, P. Dellamonica, E. Demonchy, A. De Monte, J. Durant, C. Etienne, S. Ferrando, R. Garraffo, C. Michelangeli, V. Mondain, A. Naqvi, N. Oran, I. Perbost, M. Carles, C. Klotz, A. Maka, C. Pradier, B. Prouvost- Keller, K. Risso, V. Rio, E. Rosenthal, I. Touitou, S. Wehrlen-Pugliese, G. Zouzou. Orléans: L. Hocqueloux, T. Prazuck, C. Gubavu, A. Sève, S. Giaché, V. Rzepecki, M. Colin, C. Boulard, G. Thomas. Paris APHP Bicètre: A. Cheret, C. Goujard, Y. Quertainmont, E. Teicher, N. Lerolle, S. Jaureguiberry, R. Colarino, O. Deradji, A. Castro, A. Barrail-Tran. Paris APHP Bichat: Y. Yazdanpanah, R. Landman, V. Joly, J. Ghosn, C. Rioux, S. Lariven, A. Gervais, FX. Lescure, S. Matheron, F. Louni, Z. Julia, S. Le GAC, C. Charpentier, D. Descamps, G. Peytavin. Paris APHP Necker Pasteur: C. Duvivier, C. Aguilar, F. Alby-Laurent, K. Amazzough, G. Benabdelmoumen, P. Bossi, G. Cessot, C. Charlier, P.H. Consigny, K. Jidar, E. Lafont, F. Lanternier, J. Leporrier, O. Lortholary, C. Louisin, J. Lourenco, P. Parize, B. Pilmis, C. Rouzaud, F. Touam. Paris APHP Pitié Salpetrière: MA. Valantin, R. Tubiana, R. Agher, S. Seang, L. Schneider, R. PaLich, C. Blanc, C. Katlama. Reims: F. Bani-Sadr, JL. Berger, Y. N’Guyen, D. Lambert, I. Kmiec, M. Hentzien, A. Brunet, J. Romaru, H. Marty, V. Brodard. Rennes: C. Arvieux, P. Tattevin, M. Revest, F. Souala, M. Baldeyrou, S. Patrat-Delon, J.M. Chapplain, F. Benezit, M. Dupont, M. Poinot, A. Maillard, C. Pronier, F. Lemaitre, C. Morlat, M. Poisson-Vannier, T. Jovelin, JP. Sinteff. St Etienne: A. Gagneux-Brunon, E. Botelho-Nevers, A. Frésard, V. Ronat, F. Lucht. Strasbourg: D. Rey, P. Fischer, M. Partisani, C. Cheneau, M. Priester, C. Mélounou, C. Bernard-Henry, E. de Mautort, S. Fafi-Kremer. Toulouse: P. Delobel, M. Alvarez, N. Biezunski, A. Debard, C. Delpierre, G. Gaube, P. Lansalot, L. Lelièvre, M. Marcel, G. Martin-Blondel, M. Piffaut, L. Porte, K. Saune. Tourcoing: O. Robineau, F. Ajana, E. Aïssi, I. Alcaraz, E. Alidjinou, V. Baclet, L. Bocket, A. Boucher, M. Digumber, T. Huleux, B. Lafon-Desmurs, A. Meybeck, M. Pradier, M. Tetart, P. Thill, N. Viget, M. Valette., CHU de Fort de France-Centre Hospitalier Andrée Rosemon [Cayenne, Guyane Française]-CHU Pointe-à-Pitre/Abymes [Guadeloupe] -Institut National de la Santé et de la Recherche Médicale (INSERM)-Université des Antilles et de la Guyane (UAG), and Malbec, Odile

Subjects
Microbiology (medical), Male, medicine.medical_specialty, Hepatitis C virus, [SDV]Life Sciences [q-bio], Population, men having sex with men, HIV Infections, Hepacivirus, medicine.disease_cause, Antiviral Agents, Men who have sex with men, 03 medical and health sciences, Sexual and Gender Minorities, 0302 clinical medicine, Internal medicine, medicine, Humans, 030212 general & internal medicine, Prospective Studies, Human Immunodeficiency virus, Homosexuality, Male, education, Retrospective Studies, Hepatitis, education.field_of_study, business.industry, Coinfection, Mortality rate, Incidence (epidemiology), microelimination, virus diseases, HIV, Hepatitis C, Chronic, medicine.disease, Hepatitis C, digestive system diseases, 3. Good health, [SDV] Life Sciences [q-bio], Infectious Diseases, Cohort, 030211 gastroenterology & hepatology, epidemiology, France, business
Abstract

Background The arrival of highly effective, well-tolerated, direct-acting antiviral agents (DAA) led to a dramatic decrease in hepatitis C virus (HCV) prevalence. Human immunodeficiency virus (HIV)-HCV–coinfected patients are deemed a priority population for HCV elimination, while a rise in recently acquired HCV infections in men who have sex with men (MSM) has been described. We describe the variations in HIV-HCV epidemiology in the French Dat’AIDS cohort. Methods This was a retrospective analysis of a prospective cohort of persons living with HIV (PLWH) from 2012 to 2018. We determined HCV prevalence, HCV incidence, proportion of viremic patients, treatment uptake, and mortality rate in the full cohort and by HIV risk factors. Results From 2012 to 2018, 50 861 PLWH with a known HCV status were followed up. During the period, HCV prevalence decreased from 15.4% to 13.5%. HCV prevalence among new HIV cases increased from 1.9% to 3.5% in MSM but remained stable in other groups. Recently acquired HCV incidence increased from 0.36/100 person-years to 1.25/100 person-years in MSM. The proportion of viremic patients decreased from 67.0% to 8.9%. MSM became the first group of viremic patients in 2018 (37.9%). Recently acquired hepatitis represented 59.2% of viremic MSM in 2018. DAA treatment uptake increased from 11.4% to 61.5%. More treatments were initiated in MSM in 2018 (41.2%) than in intravenous drug users (35.6%). In MSM, treatment at the acute phase represented 30.0% of treatments in 2018. Conclusions A major shift in HCV epidemiology was observed in PLWH in France from 2012 to 2018, leading to a unique situation in which the major group of HCV transmission in 2018 was MSM. Clinical Trials Registration. NCT02898987.

Published
2020
Full Text
View/download PDF

16. Reaching the Second and Third Joint United Nations Programme on HIV/AIDS 90-90-90 Targets Is Accompanied by a Dramatic Reduction in Primary Human Immunodeficiency Virus (HIV) Infection and in Recent HIV Infections in a Large French Nationwide HIV Cohort

Author

Le Guillou, Adrien, Pugliese, Pascal, Raffi, Francois, Cuzin, Lise, Katlama, Christine, Allavena, Clotilde, Dramé, Moustapha, Cotte, Laurent, Bani-Sadr, Firouzé, Orticoni, M, Soavi, M, Luquet- Besson, I, Ressiot, E, Carta- Padovani, M, Ducassou, M, Bertone, H, Galie, S, Galinier, A., Monclar, M, Ritleng, A, Ivanova, A., Blanco-Betancourt, C, Lions, C., Poizot-Martin, I., Dhiver, C., Saadia Mokhtari, M, Ménard, A, Tissot Dupont, H., Tomei, C., Meddeb, L., Belkhir, A., Ravaux, I., Alvarez, M., Biezunski, N, Debard, A., Delpierre, C., Lansalot, P, Lelievre, L., Martin-Blondel, G., Piffaut, M, Porte, L., Saune, K, Delobel, P., Breaud, S., Ceppi, C, Chirio, D, Cua, E, Dellamonica, P., Demonchy, E, De Monte, A, Durant, J., Etienne, C, Ferrando, S, Garraffo, R, Michelangeli, C, Mondain, V., Bernaud, C, Billaud, E., Biron, C, Bonnet, B., Bouchez, S, Boutoille, D., Brunet-Cartier, C, Deschanvres, C, Gaborit, B., Hall, N., Le Turnier, P., Morineau, P, Reliquet, V., Sécher, S, Cavellec, M, Soria, A., Ferre, V., André-Garnier, E., Rodallec, A., Lefebvre, M, Grossi, O, Aubry, O., Amazzough, K., Benabdelmoumen, G, Bossi, P, Cessot, G, Charlier, C., Consigny, P, Danion, F., Dureault, A, Duvivier, C., Goesch, J, Guery, R., Henry, B, Jidar, K, Lanternier, F., Loubet, P., Lortholary, O., Louisin, C, Lourenco, J, Parize, P., Pilmis, B., Touam, F, Valantin, M, Tubiana, R., Agher, R, Seang, S, Schneider, L, PaLich, R, Blanc, C., Cabié, André, Abel, S., Pierre-François, S, Pasquier, J., Guitteaud, K, Turmel, J, Illiaquer, M, Fischer, P, Partisani, M., Cheneau, C., Priester, M, Batard, M, Bernard-Henry, C, de Mautort, E, Fafi-Kremer, S., Rey, D., Chirouze, C., Gardiennet, Q, Berger, J., N’Guyen, Y, Lambert, D., Hentzien, M., Lebrun, D., Brunet, A, Kmiec, I, Brodard, V, Chidiac, C., Ferry, T., Ader, F., Biron, F., Boibieux, A., Miailhes, P., Perpoint, T., Schlienger, I, Lippmann, J, Braun, E, Koffi, J, Longuet, C., Guéripel, V, Augustin-Normand, C, Brochier, C, Degroodt, S, Atoui, N, Le Moing, V., Makinson, A., Meftah, N., de Boever, C Merle, Montes, B., Montoya Ferrer, A, Reynes, J., André, M, Boyer, L., Bouillon, M, Delestan, M, May, T., Hocqueloux, L, Prazuck, T., Gubavu, C, Sève, A, Maka, A, Boulard, C., Thomas, G, Cheret, A, Goujard, C, Quertainmont, Y, Teicher, E., Lerolle, N., Deradji, O, Barrail-Tran, A, Landman, R, Joly, V, Rioux, C., Lariven, S, gervais, a, Lescure, F., Matheron, S., Louni, F, Godard, C, Julia, Z, Chansombat, M, Rahli, D, Mackoumbou-Nkouka, C, Charpentier, C., Descamps, D., Peytavin, G., Yazdanpanah, Y., Tattevin, P., Revest, M., Souala, F., Baldeyrou, M., Patrat-Delon, S, Chapplain, J, Bénézit, F., Dupont, M., Poinot, M., Maillard, A., Pronier, C., Lemaître, F., Guennoun, C, Poisson-Vanier, M, Jovelin, T., Sinteff, J, Arvieux, C., Botelho-Nevers, E., Gagneux-Brunon, A., Frésard, A., Lucht, F., Ajana, F, Aïssi, E, Alcaraz, I, Baclet, V, Bocket, L, Boucher, A., Choisy, P, Huleux, T., Lafon-Desmurs, B., Meybeck, A, Pradier, M, Robineau, O, Viget, N, Valette, M., Hoen, B., Lamaury, I, Fabre, I, Curlier, E, Ouissa, R, Schepers, K, Herrmann-Storck, C, Dournon, N, Merrien, D, Perré, P., Guimard, T, Bollangier, O, Leautez, S, Morrier, M, Service de Maladies Infectieuses [Nice], Centre hospitalier universitaire de Nantes (CHU Nantes), Epidémiologie et analyses en santé publique : risques, maladies chroniques et handicaps (LEASP), Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service de maladies infectieuses et tropicales [Nantes], Université de Nantes (UN)-Hôtel-Dieu-Centre hospitalier universitaire de Nantes (CHU Nantes), Centre Hospitalier Universitaire de Reims (CHU Reims), Département de maladies infectieuses, Hospices Civils de Lyon (HCL), Neurobiologie, plasticité tissulaire et métabolisme énergétique (NPTME), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Centre National de la Recherche Scientifique (CNRS), Space Research Institute of the Russian Academy of Sciences (IKI), Russian Academy of Sciences [Moscow] (RAS), DDSIS 76, Hôpital Sainte-Marguerite [CHU - APHM] (Hôpitaux Sud ), Institut Hospitalier Universitaire Méditerranée Infection (IHU AMU), Microbes évolution phylogénie et infections (MEPHI), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Centre National de la Recherche Scientifique (CNRS), Istituto Nazionale di Fisica Nucleare [Sezione di Roma 1] (INFN), Istituto Nazionale di Fisica Nucleare, Service des Maladies Infectieuses et Tropicales [Hôpital de la Conception] (SMIT), Assistance Publique - Hôpitaux de Marseille (APHM)-Hôpital de la Conception [CHU - APHM] (LA CONCEPTION), Laboratoire de Physique et Chimie Quantique [Tizi-Ouzou] (LPCQ ), Université Mouloud Mammeri [Tizi Ouzou] (UMMTO), Pôle des Maladies Infectieuses et Tropicales Clinique et Biologique, Fédération de Bactériologie-Hygiène-Virologie, Assistance Publique - Hôpitaux de Marseille (APHM), Génomique métabolique (UMR 8030), Genoscope - Centre national de séquençage [Evry] (GENOSCOPE), Université Paris-Saclay-Direction de Recherche Fondamentale (CEA) (DRF (CEA)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Paris-Saclay-Direction de Recherche Fondamentale (CEA) (DRF (CEA)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Centre National de la Recherche Scientifique (CNRS)-Université d'Évry-Val-d'Essonne (UEVE), Hôpital de la Croix-Rousse [CHU - HCL], Hôpital Purpan [Toulouse], CHU Toulouse [Toulouse], Département Etude des Réacteurs (DER), CEA-Direction des Energies (ex-Direction de l'Energie Nucléaire) (CEA-DES (ex-DEN)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA), Service des maladies infectieuses, Centre Hospitalier Universitaire de Nice (CHU Nice)-University Hospital, CHU Nice [Cimiez], Hôpital Cimiez [Nice] (CHU), Unité de Nutrition Humaine - Clermont Auvergne (UNH), Université Clermont Auvergne (UCA)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Service des maladies infectieuses et tropicales [CHU Nantes], Centre de résonance magnétique biologique et médicale (CRMBM), Aix Marseille Université (AMU)-Assistance Publique - Hôpitaux de Marseille (APHM)-Centre National de la Recherche Scientifique (CNRS), Centre Hospitalier Andrée Rosemon [Cayenne, Guyane Française], Plant Biomechanics Group, Botanischer Garten, Albert-Ludwigs-Universität Freiburg, Hôtel-Dieu de Nantes, Service de virologie [CHU Nantes], Centre d'infectiologie Necker-Pasteur [CHU Necker], CHU Necker - Enfants Malades [AP-HP], Université Paris Descartes - Paris 5 (UPD5), Service de rhumatologie [Strasbourg], CHU Strasbourg-Hôpital de Hautepierre [Strasbourg], Pathogénie des infections systémiques (UMR_S 570), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Infection, Anti-microbiens, Modélisation, Evolution (IAME (UMR_S_1137 / U1137)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris 13 (UP13)-Université Paris Diderot - Paris 7 (UPD7)-Université Sorbonne Paris Cité (USPC), Service des maladies infectieuses [CHU Pitié-Salêtrière], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université, Service de Maladies Infectieuses et Tropicales [Fort-de-France, Martinique], CHU de la Martinique [Fort de France]-Hôpital Pierre Zobda-Quitman [CHU de la Martinique], CHU de la Martinique [Fort de France]-Centre Hospitalier Universitaire de Martinique [Fort-de-France, Martinique], Weill Cornell Medicine [Qatar], Institut de pharmacologie moléculaire et cellulaire (IPMC), Université Nice Sophia Antipolis (... - 2019) (UNS), COMUE Université Côte d'Azur (2015 - 2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015 - 2019) (COMUE UCA)-Centre National de la Recherche Scientifique (CNRS), Centre de Recherche en Transplantation et Immunologie (U1064 Inserm - CRTI), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN), Laboratoire de Virologie [Strasbourg], Les Hôpitaux Universitaires de Strasbourg (HUS), Laboratoire Chrono-environnement - CNRS - UFC (UMR 6249) (LCE), Centre National de la Recherche Scientifique (CNRS)-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), service de maladies infectieuses CHU J Minjoz Besancon, Hôpital Jean Minjoz, Service de Maladies Infectieuses et Tropicales [Hôpital de la Croix-Rousse - HCL], Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL), Hosp Civils Lyon, Serv Malad Infect, Lyon, France, Equipe 15, Centre de Recherche en Cancérologie de Lyon (UNICANCER/CRCL), Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Recherches Translationnelles sur le VIH et les maladies infectieuses endémiques er émergentes (TransVIHMI), Institut de Recherche pour le Développement (IRD)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Universtié Yaoundé 1 [Cameroun]-Université Cheikh Anta Diop [Dakar, Sénégal] (UCAD)-Université Montpellier 1 (UM1)-Université de Montpellier (UM), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Bell Labs (BELL), Lucent Technologies, Hôpital Bicêtre, Université Paris-Sud - Paris 11 (UP11)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Bicêtre, Centre de recherche en épidémiologie et santé des populations (CESP), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Sud - Paris 11 (UP11)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse, AP-HP - Hôpital Bichat - Claude Bernard [Paris], Registre EPIMAD, Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille)-CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-CHU Amiens-Picardie, Centre d'Etudes Lasers Intenses et Applications (CELIA), Centre National de la Recherche Scientifique (CNRS)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université de Bordeaux (UB), Pharmacie de l'Hôpital Bichat, UMR CNRS 8179, Université de Lille, Sciences et Technologies-Centre National de la Recherche Scientifique (CNRS), Service des maladies infectieuses et réanimation médicale, Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Hôpital Pontchaillou, Centre d'Investigation Clinique [Rennes] (CIC), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM), Service de pneumologie, Hôpital Pontchaillou-CHU Pontchaillou [Rennes], Centre de Physique des Particules de Marseille (CPPM), Aix Marseille Université (AMU)-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Centre National de la Recherche Scientifique (CNRS), CHU Pontchaillou [Rennes], SEV, Groupe d'Etudes et de Contrôle des Variétés et des Semences (GEVES), Service de virologie [Rennes], Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-CHU Pontchaillou [Rennes], CHU Saint-Etienne, University Hospital and University Jean Monnet, Virologie et pathogenèse virale (VPV), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS), Centre Hospitalier Tourcoing, CHU de Fort de France, Service des maladies infectieuses et tropicales, Centre Hospitalier Régional Universitaire [Besançon] (CHRU Besançon)-Hôpital Saint-Jacques, Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Pierre et Marie Curie - Paris 6 (UPMC), Université Clermont Auvergne [2017-2020] (UCA [2017-2020])-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Université Paris 13 (UP13)-Université Paris Diderot - Paris 7 (UPD7)-Université Sorbonne Paris Cité (USPC)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre Léon Bérard [Lyon]-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre Léon Bérard [Lyon], Université Montpellier 1 (UM1)-Institut de Recherche pour le Développement (IRD)-Université Cheikh Anta Diop [Dakar, Sénégal] (UCAD)-Universtié Yaoundé 1 [Cameroun]-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Hôpital Bicêtre-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris-Sud - Paris 11 (UP11), CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-CHU Amiens-Picardie-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Centre National de la Recherche Scientifique (CNRS)-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Aix Marseille Université (AMU), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université d'Évry-Val-d'Essonne (UEVE)-Centre National de la Recherche Scientifique (CNRS), Recherches Translationnelles sur le VIH et les maladies infectieuses (TransVIHMI), Centre National de la Recherche Scientifique (CNRS)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon, and Centre National de la Recherche Scientifique (CNRS)-Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)

Subjects
cascade of care, primary HIV infection, Dat’AIDS cohort, TasP, 90-90-90 target, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
Abstract

International audience; Background - In late 2013, France was one of the first countries to recommend initiation of combination antiretroviral therapy (cART) irrespective of CD4 cell count. Methods - To assess the impact of achieving the second and third Joint United Nations Programme on HIV/AIDS 90-90-90 targets (ie, 90% of diagnosed people on sustained cART, and, of those, 90% virologically controlled) on human immunodeficiency virus (HIV) incidence, we conducted a longitudinal study to describe the epidemiology of primary HIV infection (PHI) and/or recent HIV infection (patients with CD4 cell count ≥500/mm3 at HIV diagnosis; (PRHI) between 2007 and 2017 in a large French multicenter cohort. To identify changes in trends in PHI and PRHI, we used single breakpoint linear segmented regression analysis. Results - During the study period, 61 822 patients were followed in the Dat'AIDS cohort; 2027 (10.0%) had PHI and 7314 (36.1%) had PRHI. The second and third targets were reached in 2014 and 2013, respectively. The median delay between HIV diagnosis and cART initiation decreased from 9.07 (interquartile range [IQR], 1.39-33.47) months in 2007 to 0.77 (IQR, 0.37-1.60) months in 2017. A decrease in PHI (-35.1%) and PRHI (-25.4%) was observed starting in 2013. The breakpoints for PHI and PRHI were 2012.6 (95% confidence interval [CI], 2010.8-2014.4) and 2013.1 (95% CI, 2011.3-2014.8), respectively. Conclusions - Our findings show that the achievements of 2 public health targets in France and the early initiation of cART were accompanied by a reduction of about one-third in PHI and PRHI between 2013 and 2017. Clinical trials registration - NCT02898987.

Published
2020
Full Text
View/download PDF

18. Persistent low-level viraemia in antiretroviral treatment-experienced patients is not linked to viral resistance or inadequate drug concentrations

Author

Palich, R, primary, Wirden, M, additional, Peytavin, G, additional, Lê, M -P, additional, Seang, S, additional, Abdi, B, additional, Schneider, L, additional, Tubiana, R, additional, Valantin, M -A, additional, Paccoud, O, additional, Soulié, C, additional, Calvez, V, additional, Katlama, C, additional, and Marcelin, A -G, additional

Published
2020
Full Text
View/download PDF

19. Kaposi sarcoma among people living with HIV in the French DAT'AIDS cohort between 2010 and 2015

Author

Obry-Roguet, Véronique, Duvivier, Claudine, Lions, Caroline, Huleux, Thomas, Jacomet, Christine, Ferry, Tristan, Cheret, Antoine, Allavena, Clotilde, Bani-Sadr, Firouzé, Palich, Romain, Cabié, André, Pugliese, Pascal, Delobel, Pierre, Lamaury, Isabelle, Hustache-Mathieu, Laurent, Bregigeon, Sylvie, Makinson, Alain, Rey, David, Poizot-Martin, Isabelle, Hustache‐Mathieu, Laurent, Drobacheff‐Thiébaut, C., Foltzer, A., Bouiller, K., Hustache‐ Mathieu, L., Chirouze, C., LEPILLER, Q., Bozon, F., Babre, O, Brunel, A.S., Muret, P., Laurichesse, H., Lesens, O., Vidal, M., Mrozek, N., Aumeran, C., Baud, O., Corbin, V., Letertre‐Gibert, P., Casanova, S., Prouteau, J., Fabre, I., Curlier, E., Ouissa, R., Herrmann‐Storck, C., Tressieres, B., Bonijoly, T., Receveur, M.C., Boulard, F., Daniel, C., Clavel, C., Merrien, D., Perré, P., Guimard, T., Bollangier, O., Leautez, S., Morrier, M., Laine, L., Ader, F., Becker, A., Biron, F., Boibieux, A., Cotte, L., Miailhes, P., Perpoint, T., Roux, S., Triffault‐Fillit, C., Degroodt, S., Brochier, C., Valour, F., Chidiac, C., Ménard, A., Belkhir, A.Y., Colson, P., Dhiver, C., Madrid, A., Martin‐Degioanni, M., Meddeb, L., Mokhtari, M., Motte, A., Raoux, A., Ravaux, I., Tamalet, C., Tomei, C., Tissot Dupont, H., Zaegel‐Faucher, O., Obry‐Roguet, Véronique, Laroche, H, Orticoni, M., Soavi, M.J., Geneau de Lamarlière, P, Ressiot, E, Ducassou, M.J., Jaquet, I., Galie, S., Galinier, A., Martinet, P., Landon, M., Ritleng, A.S., Ivanova, A., Debreux, C., Poizot‐Martin, I., Abel, S., Cabras, O., Cuzin, L., Guitteaud, K., Illiaquer, M., Pierre‐François, S., Osei, L., Pasquier, J., Rome, K., Sidani, E., Turmel, JM, Varache, C., Atoui, N., Bistoquet, M., Delaporte, E., Le Moing, V., Meftah, N., Merle de Boever, C., Montes, B., Montoya Ferrer, A., Tuaillon, E., Reynes, J., André, M., Boyer, L., Bouillon, MP., Delestan, M., Rabaud, C., May, T., Hoen, B., Bernaud, C., Billaud, E., Biron, C., Bonnet, B., Bouchez, S., Boutoille, D., Brunet‐Cartier, C., Deschanvres, C., Hall, N., Morineau, P., Reliquet, V., Sécher, S., Cavellec, M., Soria, A., Paredes, E., Ferre, V., André‐Garnier, E., Rodallec, A., Lefebvre, M., Grossi, O., Aubry, O., Raffi, F., Breaud, S., Ceppi, C., Chirio, D., Cua, E., Dellamonica, P., Demonchy, E., De Monte, A., Durant, J., Etienne, C., Ferrando, S., Garraffo, R., Michelangeli, C., Mondain, V., Naqvi, A., Oran, N., Perbost, I., Pillet, S., Pradier, C., Prouvost‐Keller, B., Risso, K., Rio, V., Roger, PM., Rosenthal, E., Sausse, S., Touitou, I., Wehrlen‐Pugliese, S., Zouzou, G., Hocqueloux, L., Prazuck, T., Gubavu, C., Sève, A., Maka, A., Boulard, C., Thomas, G., Lerolle, N., Landman, R., Joly, V., Ghosn, J., Rioux, C., Lariven, S., Gervais, A., Lescure, F.X., Matheron, S., Louni, F., Julia, Z., Mackoumbou‐Nkouka, C., Le Gac, S., Charpentier, C., Descamps, D., Peytavin, G., Yazdanpanah, Y., Amazzough, K., Benabdelmoumen, G., Bossi, P., Cessot, G., Charlier, C., Consigny, P.H., Danion, F., Dureault, A., Goesch, J., Guery, R., Henry, B., Jidar, K., Lanternier, F., Loubet, P., Lortholary, O., Louisin, C., Lourenco, J., Parize, P., Pilmis, B., Touam, F, Valantin, M.A., Tubiana, R., Agher, R, Seang, S., Schneider, L., Blanc, C., Katlama, C., Berger, J.L., N'guyen, Y., Lambert, D., Kmiec, I., Hentzien, M., Brunet, A., Brodard, V., Bani‐Sadr, Firouze, Tattevin, P., Revest, M., Souala, F., Baldeyrou, M., Patrat‐Delon, S., Chapplain, J.M., Bénézit, F., Dupont, M., Poinot, M., Maillard, A., Pronier, C., Lemaitre, F., Guennoun, C., Poisson‐Vanier, M., Jovelin, T., Sinteff, J.P., Arvieux, C., Botelho‐Nevers, E., Gagneux‐Brunon, A., Frésard, Anne, Ronat, V., Lucht, F., Fischer, P., Partisani, M., Cheneau, C., Priester, M, Batard, ML, Bernard‐Henry, C, de Mautort, E, Fafi‐Kremer, S., Alvarez, M., Biezunski, N., Debard, A., Delpierre, C., Lansalot, P., Lelievre, L., Martin‐Blondel, G., Piffaut, M., Porte, L., Saune, K., Ajana, F., Aïssi, E., Alcaraz, I., Baclet, V., Bocket, L., Boucher, A., Choisy, P., Lafon‐Desmurs, B., Meybeck, A., Pradier, M., Robineau, O., Viget, N., Valette, M., Hôpital Sainte-Marguerite [CHU - APHM] (Hôpitaux Sud ), Centre d'infectiologie Necker-Pasteur [CHU Necker], CHU Necker - Enfants Malades [AP-HP], Sciences Economiques et Sociales de la Santé & Traitement de l'Information Médicale (SESSTIM - U1252 INSERM - Aix Marseille Univ - UMR 259 IRD), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Hospitalier Tourcoing, Département des Maladies Infectieuses et Tropicales [CHU Gabriel-Montpied, Clermont-Ferrand], CHU Gabriel Montpied [Clermont-Ferrand], Pathogénie des Staphylocoques – Staphylococcal Pathogenesis, Centre International de Recherche en Infectiologie - UMR (CIRI), École normale supérieure - Lyon (ENS Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-École normale supérieure - Lyon (ENS Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Services des maladies infectieuses [CH Turcoing], Centre Hospitalier de Tourcoing, Service de maladies infectieuses et tropicales [Nantes], Université de Nantes (UN)-Hôtel-Dieu-Centre hospitalier universitaire de Nantes (CHU Nantes), Centre Hospitalier Universitaire de Reims (CHU Reims), Alliance for International medical Action (ALIMA), Service de Maladies Infectieuses et Tropicales [Fort-de-France, Martinique], CHU de la Martinique [Fort de France]-Hôpital Pierre Zobda-Quitman [CHU de la Martinique], CHU de la Martinique [Fort de France]-Centre Hospitalier Universitaire de Martinique [Fort-de-France, Martinique], Service de Maladies Infectieuses [Nice], Centre de Physiopathologie Toulouse Purpan ex IFR 30 et IFR 150 (CPTP), Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), CHU Pointe-à-Pitre/Abymes [Guadeloupe], service de maladies infectieuses CHU J Minjoz Besancon, Hôpital Jean Minjoz, Service d'Immuno-hématologie clinique [Hôpital Sainte Marguerite - APHM], Assistance Publique - Hôpitaux de Marseille (APHM)-Hôpital Sainte-Marguerite [CHU - APHM] (Hôpitaux Sud ), Recherches Translationnelles sur le VIH et les maladies infectieuses endémiques er émergentes (TransVIHMI), Institut de Recherche pour le Développement (IRD)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Universtié Yaoundé 1 [Cameroun]-Université Cheikh Anta Diop [Dakar, Sénégal] (UCAD)-Université Montpellier 1 (UM1)-Université de Montpellier (UM), Laboratoire d'Ingénierie Circulation Transport (LICIT), Institut Français des Sciences et Technologies des Transports, de l'Aménagement et des Réseaux (IFSTTAR)-École Nationale des Travaux Publics de l'État (ENTPE)-Université de Lyon, Laboratoire Chrono-environnement - CNRS - UFC (UMR 6249) (LCE), Centre National de la Recherche Scientifique (CNRS)-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), Centre Hospitalier Universitaire de Besançon (CHU Besançon), Université libre de Bruxelles (ULB), Hôpital Gabriel Montpied, Service des Maladies Infectieuses et Tropicales, Centre Hospitalier Universitaire de Clermont-Ferrand, Laboratoire Microorganismes : Génome et Environnement - Clermont Auvergne (LMGE), Université Clermont Auvergne (UCA)-Centre National de la Recherche Scientifique (CNRS), CHU Gabriel Montpied (CHU), CHU Clermont-Ferrand, CCLIN Sud-Est – Centre de Coordination de la Lutte contre les Infections Nosocomiales Sud-Est, Montpellier Research in Management (MRM), Université Montpellier 1 (UM1)-Université Paul-Valéry - Montpellier 3 (UPVM)-Université Montpellier 2 - Sciences et Techniques (UM2)-Université de Perpignan Via Domitia (UPVD)-Groupe Sup de Co Montpellier (GSCM) - Montpellier Business School-Université de Montpellier (UM), Laboratoire Traitement et Communication de l'Information (LTCI), Télécom ParisTech-Institut Mines-Télécom [Paris] (IMT)-Centre National de la Recherche Scientifique (CNRS), Pathologies Pulmonaires et Plasticité Cellulaire - UMR-S 1250 (P3CELL), Université de Reims Champagne-Ardenne (URCA)-Institut National de la Santé et de la Recherche Médicale (INSERM), Hosp Civils Lyon, Serv Malad Infect, Lyon, France, Institut de biologie et chimie des protéines [Lyon] (IBCP), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS), Hôpital de la Croix-Rousse [CHU - HCL], Hospices Civils de Lyon (HCL), Centre Hospitalier Lyon Sud [CHU - HCL] (CHLS), Equipe 15, Centre de Recherche en Cancérologie de Lyon (UNICANCER/CRCL), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre Léon Bérard [Lyon]-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre Léon Bérard [Lyon], Service de Maladies Infectieuses et Tropicales [Hôpital de la Croix-Rousse - HCL], Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL), Institut Hospitalier Universitaire Méditerranée Infection (IHU AMU), Microbes évolution phylogénie et infections (MEPHI), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Centre National de la Recherche Scientifique (CNRS), Neurobiologie, plasticité tissulaire et métabolisme énergétique (NPTME), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Centre National de la Recherche Scientifique (CNRS), CECIL, Space Research Institute of the Russian Academy of Sciences (IKI), Russian Academy of Sciences [Moscow] (RAS), Système membranaires, photobiologie, stress et détoxication (SMPSD), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Centre National de la Recherche Scientifique (CNRS), Epidémiologie et analyses en santé publique : risques, maladies chroniques et handicaps (LEASP), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre IRD de Montpellier (IRD), Cellules Souches, Plasticité Cellulaire, Médecine Régénératrice et Immunothérapies (IRMB), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Centre d'études et de recherche sur les services de santé et la qualité de vie (CEReSS), Aix Marseille Université (AMU), Service des Maladies Infectieuses et Tropicales [CHRU Nancy], Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Bell Labs (BELL), Lucent Technologies, Service des maladies infectieuses et tropicales, Centre Hospitalier Régional Universitaire [Besançon] (CHRU Besançon)-Hôpital Saint-Jacques, Centre hospitalier universitaire de Nantes (CHU Nantes), Unité de Nutrition Humaine - Clermont Auvergne (UNH), Institut National de la Recherche Agronomique (INRA)-Université Clermont Auvergne (UCA), Service des maladies infectieuses et tropicales [CHU Nantes], Plant Biomechanics Group, Botanischer Garten, Albert-Ludwigs-Universität Freiburg, Service de virologie [CHU Nantes], Centre de recherche en neurosciences de Lyon (CRNL), Université de Lyon-Université de Lyon-Université Jean Monnet [Saint-Étienne] (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Service des maladies infectieuses, Centre Hospitalier Universitaire de Nice (CHU Nice)-University Hospital, CHU Nice [Cimiez], Hôpital Cimiez [Nice] (CHU), Centre Hospitalier Universitaire de Nice (CHU Nice), Hopital l'Archet, Centre d'Information et de Soins de I'Immunodéficience Humaine (CISIH). Hôpital l'Archet 1, Hôpital l'Archet, Public Health Department, Hôpital de l'Archet, Institut de génétique humaine (IGH), Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS), Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Pierre et Marie Curie - Paris 6 (UPMC), Centre de recherche en épidémiologie et santé des populations (CESP), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Sud - Paris 11 (UP11)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse, Infectious Diseases Department, Université Montpellier 1 (UM1), AP-HP - Hôpital Bichat - Claude Bernard [Paris], Centre Régional de recherche et de Formation à la prise en charge Clinique de Fann (CRCF), CHNU Fann, Registre EPIMAD, CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-CHU Amiens-Picardie-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Centre d'Etudes Lasers Intenses et Applications (CELIA), Centre National de la Recherche Scientifique (CNRS)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université de Bordeaux (UB), Pharmacie de l'Hôpital Bichat, UMR CNRS 8179, Université de Lille, Sciences et Technologies-Centre National de la Recherche Scientifique (CNRS), Université Paris Descartes - Paris 5 (UPD5), Service de rhumatologie [Strasbourg], CHU Strasbourg-Hôpital de Hautepierre [Strasbourg], Pathogénie des infections systémiques (UMR_S 570), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Infection, Anti-microbiens, Modélisation, Evolution (IAME (UMR_S_1137 / U1137)), Université Paris 13 (UP13)-Université Paris Diderot - Paris 7 (UPD7)-Université Sorbonne Paris Cité (USPC)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service des maladies infectieuses [CHU Pitié-Salêtrière], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université, Service des maladies infectieuses et tropicales [CHU Pitié-Salpêtrière], Laboratoire d'aérologie (LA), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Observatoire Midi-Pyrénées (OMP), Institut de Recherche pour le Développement (IRD)-Centre National de la Recherche Scientifique (CNRS)-Université Fédérale Toulouse Midi-Pyrénées-Centre National d'Études Spatiales [Toulouse] (CNES)-Météo France-Institut de Recherche pour le Développement (IRD)-Centre National de la Recherche Scientifique (CNRS)-Centre National d'Études Spatiales [Toulouse] (CNES)-Météo France-Centre National de la Recherche Scientifique (CNRS), McGill University = Université McGill [Montréal, Canada], Service des maladies infectieuses et réanimation médicale, Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Hôpital Pontchaillou, Centre d'Investigation Clinique [Rennes] (CIC), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM), Les Hôpitaux Universitaires de Strasbourg (HUS), Service de pneumologie, Hôpital Pontchaillou-CHU Pontchaillou [Rennes], CHU Pontchaillou [Rennes], SEV, Groupe d'Etudes et de Contrôle des Variétés et des Semences (GEVES), Service de virologie [Rennes], Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-CHU Pontchaillou [Rennes], Centre Hospitalier Universitaire de Saint-Etienne (CHU de Saint-Etienne), University Hospital and University Jean Monnet, Institut de pharmacologie moléculaire et cellulaire (IPMC), Université Nice Sophia Antipolis (... - 2019) (UNS), COMUE Université Côte d'Azur (2015 - 2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015 - 2019) (COMUE UCA)-Centre National de la Recherche Scientifique (CNRS), Centre de Recherche en Transplantation et Immunologie (U1064 Inserm - CRTI), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN), Génomique métabolique (UMR 8030), Genoscope - Centre national de séquençage [Evry] (GENOSCOPE), Direction de Recherche Fondamentale (CEA) (DRF (CEA)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Paris-Saclay-Direction de Recherche Fondamentale (CEA) (DRF (CEA)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Paris-Saclay-Université d'Évry-Val-d'Essonne (UEVE)-Centre National de la Recherche Scientifique (CNRS), Virologie et pathogenèse virale (VPV), Institut Pasteur [Paris] (IP)-CHU Necker - Enfants Malades [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Imagine - Institut des maladies génétiques (IHU) (Imagine - U1163), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité), Institut Cochin (IC UM3 (UMR 8104 / U1016)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Cité (UPCité), Institut Pasteur [Paris] (IP), Centre Hospitalier Gustave Dron [Tourcoing], Infection à VIH, réservoirs, diversité génétique et résistance aux antirétroviraux (ARV) (EA 7327), AP-HP Hôpital Bicêtre (Le Kremlin-Bicêtre), Département d'Hématologie Clinique [CHU Nantes] (Hôtel-Dieu), Hôtel-Dieu de Nantes-Centre hospitalier universitaire de Nantes (CHU Nantes), Hôpital Robert Debré, Hôpital Robert Debré-Centre Hospitalier Universitaire de Reims (CHU Reims), CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), Centre Hospitalier Universitaire de Martinique [Fort-de-France, Martinique], Maladies infectieuses et tropicales dans la Caraïbe (MAITC EA 4537), CHU Pointe-à-Pitre/Abymes [Guadeloupe] -CHU de la Martinique [Fort de France]-Université des Antilles (UA), Centre d'Investigation Clinique Antilles-Guyane (CIC - Antilles Guyane), Université des Antilles et de la Guyane (UAG)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pointe-à-Pitre/Abymes [Guadeloupe] -CHU de Fort de France-Centre Hospitalier Andrée Rosemon [Cayenne, Guyane Française], Centre Hospitalier Universitaire de Saint-Etienne [CHU Saint-Etienne] (CHU ST-E), Centre de Physiopathologie Toulouse Purpan (CPTP), Université de Toulouse (UT)-Université de Toulouse (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Service Maladies infectieuses et tropicales [CHU Toulouse], Pôle Inflammation, infection, immunologie et loco-moteur [CHU Toulouse] (Pôle I3LM Toulouse), Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Dermatologie et Maladies infectieuses [Pointe-à-Pitre], CHU Pointe-à-Pitre/Abymes [Guadeloupe] -Centre de Gestion du Risque Infectieux Nosocomial [Pointe-à-Pitre] (CGRIN), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Infectious and Tropical Diseases Department [Montpellier], Institut de Recherche pour le Développement (IRD)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Institut National de la Santé et de la Recherche Médicale (INSERM), Dat'AIDS study group: C Drobacheff-Thiébaut, A Foltzer, K Bouiller, C Chirouze, Q Lepiller, F Bozon, O Babre, A S Brunel, P Muret, H Laurichesse, O Lesens, M Vidal, N Mrozek, C Aumeran, O Baud, V Corbin, P Letertre-Gibert, S Casanova, J Prouteau, I Fabre, E Curlier, R Ouissa, C Herrmann-Storck, B Tressieres, T Bonijoly, M C Receveur, F Boulard, C Daniel, C Clavel, D Merrien, P Perré, T Guimard, O Bollangier, S Leautez, M Morrier, L Laine, F Ader, A Becker, F Biron, A Boibieux, L Cotte, P Miailhes, T Perpoint, S Roux, C Triffault-Fillit, S Degroodt, C Brochier, F Valour, C Chidiac, A Ménard, A Y Belkhir, P Colson, C Dhiver, A Madrid, M Martin-Degioanni, L Meddeb, M Mokhtari, A Motte, A Raoux, I Ravaux, C Tamalet, C Toméi, H Tissot Dupont, O Zaegel-Faucher, H Laroche, M Orticoni, M J Soavi, P Geneau de Lamarlière, E Ressiot, M J Ducassou, I Jaquet, S Galie, A Galinier, P Martinet, M Landon, A S Ritleng, A Ivanova, C Debreux, S Abel, O Cabras, L Cuzin, K Guitteaud, M Illiaquer, S Pierre-François, L Osei, J Pasquier, K Rome, E Sidani, J M Turmel, C Varache, N Atoui, M Bistoquet, E Delaporte, V Le Moing, N Meftah, C Merle de Boever, B Montes, A Montoya Ferrer, E Tuaillon, J Reynes, M André, L Boyer, M P Bouillon, M Delestan, C Rabaud, T May, B Hoen, C Bernaud, E Billaud, C Biron, B Bonnet, S Bouchez, D Boutoille, C Brunet-Cartier, C Deschanvres, N Hall, T Jovelin, P Morineau, V Reliquet, S Sécher, M Cavellec, A Soria, E Paredes, V Ferré, E André-Garnier, A Rodallec, M Lefebvre, O Grossi, O Aubry, F Raffi, S Breaud, C Ceppi, D Chirio, E Cua, P Dellamonica, E Demonchy, A De Monte, J Durant, C Etienne, S Ferrando, R Garraffo, C Michelangeli, V Mondain, A Naqvi, N Oran, I Perbost, S Pillet, C Pradier, B Prouvost-Keller, K Risso, V Rio, P M Roger, E Rosenthal, S Sausse, I Touitou, S Wehrlen-Pugliese, G Zouzou, L Hocqueloux, T Prazuck, C Gubavu, A Sève, A Maka, C Boulard, G Thomas, C Goujard, Y Quertainmont, E Teicher, N Lerolle, O Deradji, A Barrail-Tran, R Landman, V Joly, J Ghosn, C Rioux, S Lariven, A Gervais, F X Lescure, S Matheron, F Louni, Z Julia, C Mackoumbou-Nkouka, S Le Gac, C Charpentier, D Descamps, G Peytavin, Y Yazdanpanah, K Amazzough, G Benabdelmoumen, P Bossi, G Cessot, C Charlier, P H Consigny, F Danion, A Dureault, J Goesch, R Guery, B Henry, K Jidar, F Lanternier, P Loubet, O Lortholary, C Louisin, J Lourenco, P Parize, B Pilmis, F Touam, M A Valantin, R Tubiana, R Agher, S Seang, L Schneider, C Blanc, C Katlama, J L Berger, Y N'Guyen, D Lambert, I Kmiec, M Hentzien, A Brunet, V Brodard, P Tattevin, M Revest, F Souala, M Baldeyrou, S Patrat-Delon, J M Chapplain, F Benezit, M Dupont, M Poinot, A Maillard, C Pronier, F Lemaitre, C Guennoun, M Poisson-Vanier, T Jovelin, J P Sinteff, C Arvieux, E Botelho-Nevers, A Gagneux-Brunon, A Frésard, V Ronat, F Lucht, P Fischer, M Partisani, C Cheneau, M Priester, M L Batard, C Bernard-Henry, E de Mautort, S Fafi-Kremer, M Alvarez, N Biezunski, A Debard, C Delpierre, P Lansalot, L Lelièvre, G Martin-Blondel, M Piffaut, L Porte, K Saune, F Ajana, E Aïssi, I Alcaraz, V Baclet, L Bocket, A Boucher, P Choisy, B Lafon-Desmurs, A Meybeck, M Pradier, O Robineau, N Viget, M Valette., Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut Pasteur [Paris], Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Paris (UP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université de Paris (UP), Institut Pasteur [Paris], Sorbonne Université (SU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut National de la Santé et de la Recherche Médicale (INSERM)-École normale supérieure - Lyon (ENS Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-École normale supérieure - Lyon (ENS Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université Clermont Auvergne [2017-2020] (UCA [2017-2020])-Centre National de la Recherche Scientifique (CNRS), Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 (UCBL), Centre National de la Recherche Scientifique (CNRS)-Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU), Institut National de la Recherche Agronomique (INRA)-Université Clermont Auvergne [2017-2020] (UCA [2017-2020]), Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille)-CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-CHU Amiens-Picardie, Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris 13 (UP13)-Université Paris Diderot - Paris 7 (UPD7)-Université Sorbonne Paris Cité (USPC), Université Paris-Saclay-Direction de Recherche Fondamentale (CEA) (DRF (CEA)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université d'Évry-Val-d'Essonne (UEVE)-Centre National de la Recherche Scientifique (CNRS), Recherches Translationnelles sur le VIH et les maladies infectieuses (TransVIHMI), Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut de Recherche pour le Développement (IRD)-Université Montpellier 1 (UM1)-Université Cheikh Anta Diop [Dakar, Sénégal] (UCAD)-Universtié Yaoundé 1 [Cameroun]-Université de Montpellier (UM), Université Paul-Valéry - Montpellier 3 (UPVM)-Université Montpellier 2 - Sciences et Techniques (UM2)-Université de Perpignan Via Domitia (UPVD)-Université Montpellier 1 (UM1)-Groupe Sup de Co Montpellier (GSCM) - Montpellier Business School-Université de Montpellier (UM), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Université Paris-Sud - Paris 11 (UP11)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre National de la Recherche Scientifique (CNRS)-Observatoire Midi-Pyrénées (OMP), Institut de Recherche pour le Développement (IRD)-Centre National de la Recherche Scientifique (CNRS)-Université Fédérale Toulouse Midi-Pyrénées-Centre National d'Études Spatiales [Toulouse] (CNES)-Météo France-Institut de Recherche pour le Développement (IRD)-Centre National de la Recherche Scientifique (CNRS)-Université Fédérale Toulouse Midi-Pyrénées-Centre National d'Études Spatiales [Toulouse] (CNES)-Météo France-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées, Centre National de la Recherche Scientifique (CNRS)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon, and Dupuis, Christine

Subjects
0301 basic medicine, Pediatrics, medicine.medical_specialty, MESH: Sarcoma, Kaposi* / epidemiology, [SDV]Life Sciences [q-bio], 030106 microbiology, HIV Infections, Dermatology, Skin Infectiology, Venereology and Sexual Health, 03 medical and health sciences, 0302 clinical medicine, Acquired immunodeficiency syndrome (AIDS), medicine, Humans, MESH: HIV Infections* / complications, 030212 general & internal medicine, Sarcoma, Kaposi, Retrospective Studies, Response rate (survey), MESH: Acquired Immunodeficiency Syndrome, MESH: Herpesvirus 8, Human, Acquired Immunodeficiency Syndrome, MESH: Humans, business.industry, Kaposi sarcoma, HIV, Retrospective cohort study, MESH: Retrospective Studies, MESH: HIV Infections* / drug therapy, medicine.disease, 3. Good health, [SDV] Life Sciences [q-bio], medical dermatology, Regimen, Infectious Diseases, Clinical research, clinical research, Herpesvirus 8, Human, Cohort, oncology, Original Article, Sarcoma, business, Viral load, MESH: HIV Infections* / epidemiology, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
Abstract

International audience; Background - Although antiretroviral therapy (ART) has reduced the risk of Kaposi sarcoma (KS), KS cases still occur in HIV-infected people. Objective - To describe all KS cases observed between 2010 and 2015 in a country with high ART coverage. Methods - Retrospective study using longitudinal data from 44 642 patients in the French Dat'AIDS multicenter cohort. Patients' characteristics were described at KS diagnosis according to ART exposure and to HIV-plasma viral load (HIV-pVL) (≤50 or >50) copies/mL. Results - Among the 209 KS cases diagnosed during the study period, 33.2% occurred in ART naïve patients, 17.3% in ART-experienced patients and 49.5% in patients on ART, of whom 23% for more than 6 months. Among these patients, 24 (11.5%) had HIV-pVL ≤50 cp/mL, and 16 (66%) were treated with a boosted-PI-based regimen. The distribution of KS localization did not differ by ART status nor by year of diagnosis. Limitations - Data on human herpesvirus 8, treatment modalities for KS and response rate were not collected. Conclusion - Half of KS cases observed in the study period occurred in patients not on ART, reflecting the persistence of late HIV diagnosis. Factors associated with KS in patients on ART with HIV-pVL ≤50 cp/mL remain to be explored.

Published
2020
Full Text
View/download PDF

20. Decreased darunavir concentrations during once-daily co-administration with maraviroc and raltegravir: OPTIPRIM-ANRS 147 trial

Author

Pressiat, Claire, Hirt, Déborah, Treluyer, Jean-Marc, Zheng, Yi, Morlat, Philippe, Naqvi, Alice, Tran, Laurent, Viard, Jean-Paul, Avettand-Fenoel, Véronique, Rouzioux, Christine, Meyer, Laurence, Cheret, Antoine, Hoen, B, Bourdeaux, C, Delfraissy, J, Goujard, C, Amri, I, Fourn, E, Quertainmont, Y, Môle, M, Rami, A, Durel, A, Diemer, M, Parrinello, M, Allègre, T, Lafeuillade, A, Hittinger, G, Lambry, V, Carrerre, M, Philip, G, Duvivier, C, Consigny, P, Charlier, C, Shoai, M, Touam, F, Pialoux, G, Slama, L, l'Yavanc, T, Mathurin, P, Adda, A, Berrebi, V, Salmon, D, Chakvetadze, E, Tassadit, T, Ousseima, E, Pietri, M, Levy, Y, Lascaux, A, Lelievre, J, Giovanna, M, Dominguez, S, Dumont, C, Katlama, C, Valentin, M, Seang, S, Schneider, L, Kiorza, N, Chermak, A, Ben Abdallah, S, Simon, A, Pichon, F, Pauchard, M, Molina, J, Lascoux, C, Ponscarme, D, Colin de Verdiere, N, Scemla, A, de Castro, N, Rachline, A, Garrait, V, Rozenbaum, W, Ferret, S, Balkan, S, Clavel, F, Tourdjman, M, Lafaurie, M, Aslan, A, Goguel, J, Thierry, S, de Lastours, V, Gallien, S, Pavie, J, Delgado, J, Mededji, C, Veron, R, Abel, S, Pierre-François, S, Baringhton, C, Chennebault, J, Vandamme, Y, Fialaire, P, Rehaiem, S, Rabier, V, Abgueguen, P, Vandenhende, M, Bernard, N, Lacoste, D, Michaux, C, Paccalin, F, Receveur, M, Caldato, S, Delaune, J, Ragnaud, J, Neau, D, Lacaze-Buzy, L, Livrozet, J, Jeanblanc, F, Makhloufi, D, Brunel Dalmas, F, Jourdain, J, Chiarello, P, Yeni, P, Phung, B, Rioux, C, Godard, C, Louni, F, El Alami Talbi, N, Catalano, G, Guiroy, F, Reynes, J, Jacquet, J, Fauchere, V, Merle, C, Lemoine, V, Loriette, M, Morquin, D, Makinson, A, Atoui, N, Tramoni, C, Raffi, F, Allavena, C, Bonnet, B, Bouchez, S, Feuillebois, N, Brunet-François, C, Reliquet, V, Mounoury, O, Morineau-Le-Houssine, P, Billaud, E, Brosseau, D, Hüe, H, Dellamonica, P, Vassallo, M, Leplatois, A, Durant, J, Joulié, A, Souala, F, Michelet, C, Arvieux, C, Tattevin, P, Leroy, H, Revest, M, Fily, F, Chapplain, J, Ratajczak, C, Gras, G, Bernard, L, Dailloux, J, Laplantine, V, Cuzin, L, Marchou, B, Larrigue, S, Chauveau, M, Balsarin, F, Obadia, M, Bonne, S, Huleux, T, Ajana, F, Alcaraz, I, Baclet, V, Melliez, H, Viget, N, de la Tribonniere, X, Aissi, E, Poissy, J, Ravaux, I, Vallon, A, Varan, M, May, T, Letranchant, L, Burty, C, Briaud, A, Wassoumbou, S, Stenzel, M, Bouillon, M, Debab, Y, Caron, F, Gueit, I, Chapuzet, C, Borsa Lebas, F, Etienne, M, Miailhes, P, Perpoint, T, Senechal, A, Schlienger, I, Cotte, L, Augustin Normand, C, Boibieux, A, Ferry, T, Corsini, N, Braun, E, Lippran, J, Biron, F, Chidiac, C, Pailhes, S, Lipman, J, Koffi, J, Thoirain, V, Brochier, C, Greder Belan, A, Therby, A, Monnier, S, Ruquet, M, Richier, L, Prevoteau Du Clary, F, Evaluation thérapeutique et pharmacologie périnatale et pédiatrique (EA_7323), Université Paris Descartes - Paris 5 (UPD5), Bordeaux population health (BPH), Université de Bordeaux (UB)-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service de médecine interne et maladies infectieuses [Bordeaux], CHU Bordeaux [Bordeaux]-Groupe hospitalier Saint-André, Service de Maladies Infectieuses [CHU Nice], Hôpital l'Archet - CHU de Nice, Centre de recherche en épidémiologie et santé des populations (CESP), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Université Paris-Sud - Paris 11 (UP11)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre de Diagnostic et de Thérapeutique, Hôpital de l’Hôtel-Dieu [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Infection à VIH, réservoirs, diversité génétique et résistance aux antirétroviraux (ARV) (EA 7327), Laboratoire de Virologie [CHU Necker], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Necker - Enfants Malades [AP-HP], Service de Médecine Interne - Immunologie Clinique [AP-HP Bicêtre], AP-HP Hôpital Bicêtre (Le Kremlin-Bicêtre), Stratégies thérapeutiques contre l'infection VIH et les maladies virales associées [iPLesp] (THERAVIR), Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), ARN régulateurs bactériens et médecine (BRM), Université de Rennes (UR)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), and CHU Pontchaillou [Rennes]

Subjects
Male, 0301 basic medicine, MESH: Raltegravir Potassium, [SDV]Life Sciences [q-bio], HIV Infections, Pharmacology, Maraviroc, MESH: HIV-1, Plasma, chemistry.chemical_compound, Pharmacology (medical), MESH: Anti-HIV Agents, MESH: Maraviroc, Darunavir, MESH: Darunavir, education.field_of_study, MESH: Middle Aged, MESH: HIV Infections, Middle Aged, Viral Load, Infectious Diseases, MESH: Young Adult, Female, MESH: Viral Load, Viral load, medicine.drug, Adult, Microbiology (medical), Anti-HIV Agents, 030106 microbiology, Population, Emtricitabine, Young Adult, 03 medical and health sciences, Pharmacokinetics, Raltegravir Potassium, medicine, Humans, education, MESH: Plasma, Models, Statistical, Ritonavir, MESH: Humans, business.industry, MESH: Adult, Raltegravir, MESH: Male, 030104 developmental biology, chemistry, HIV-1, MESH: Ritonavir, business, MESH: Female, MESH: Models, Statistical
Abstract

International audience; BackgroundThe OPTIPRIM-ANRS 147 trial compared intensive combination ART (darunavir/ritonavir, tenofovir disoproxil fumarate/emtricitabine, raltegravir and maraviroc) started early during primary HIV-1 infection with standard tritherapy with darunavir/ritonavir, tenofovir disoproxil fumarate and emtricitabine. From month 6 to 18, the percentage of viral load values

Published
2018
Full Text
View/download PDF

22. Safety study and therapeutic drug monitoring of the oral tablet formulation of posaconazole in patients with haematological malignancies

Author

Lemaitre, Florian, Le Guillou, Adrien, Pugliese, Pascal, Raffi, François, Cuzin, Lise, Katlama, Christine, Allavena, Clotilde, Dramé, Moustapha, Cotte, Laurent, Bani-Sadr, Firouzé, Orticoni, M, Soavi, M, Luquet- Besson, I, Ressiot, E, Carta- Padovani, M, Ducassou, M, Bertone, H, Galie, S, Galinier, A., Monclar, M, Ritleng, A, Ivanova, A., Blanco-Betancourt, C, Lions, C., Poizot-Martin, I., Dhiver, C, Saadia Mokhtari, M, Menard, A., Tissot Dupont, H, Toméi, C, Meddeb, L., Belkhir, A., Ravaux, I., Alvarez, M., Biezunski, N, Debard, A., Delpierre, C, Lansalot, P, Lelievre, L., Martin-Blondel, G., Piffaut, M, Porte, L., Saune, K, Delobel, P., Breaud, S., Ceppi, C, Chirio, D, Cua, E, Dellamonica, P., Demonchy, E, De Monte, A, Durant, J., Etienne, C, Ferrando, S, Garraffo, R, Michelangeli, C, Mondain, V., Bernaud, C, Billaud, E., Biron, C, Bonnet, B, Bouchez, S, Boutoille, D., Brunet-Cartier, C, Deschanvres, C, Gaborit, B., Hall, N, Le Turnier, P., Morineau, P, Reliquet, V., Sécher, S, Cavellec, M, Soria, A., Ferre, V., André-Garnier, E., Rodallec, A., Lefebvre, M, Grossi, O, Aubry, O., Amazzough, K., Benabdelmoumen, G, Bossi, P, Cessot, G, Charlier, C., Consigny, P, Danion, F., Dureault, A, Duvivier, C., Goesch, J, Guery, R., Henry, B., Jidar, K, Lanternier, F., Loubet, P., Lortholary, O., Louisin, C, Lourenco, J, Parize, P., Pilmis, B., Touam, F, Valantin, M, Tubiana, R., Agher, R, Seang, S, Schneider, L, PaLich, R, Blanc, C, Cabié, André, Abel, S., Pierre-François, S, Pasquier, J., Guitteaud, K, Turmel, J, Illiaquer, M, Fischer, P., Partisani, M., Cheneau, C., Priester, M, Batard, M, Bernard-Henry, C, de Mautort, E, Fafi-Kremer, S., Rey, D., Chirouze, C., Gardiennet, Q, Berger, J, N’Guyen, Y, Lambert, D., Hentzien, M., Lebrun, D., Brunet, A, Kmiec, I, Brodard, V, Chidiac, C., Ferry, T., Ader, F., Biron, F., Boibieux, A., Miailhes, P., Perpoint, T., Schlienger, I, Lippmann, J, Braun, E, Koffi, J, Longuet, C., Guéripel, V, Augustin-Normand, C, Brochier, C, Degroodt, S, Atoui, N, Le Moing, V., Makinson, A., Meftah, N., de Boever, C Merle, Montes, B, Montoya Ferrer, A, Reynes, J., Andre, M., Boyer, L, Bouillon, M, Delestan, M, May, T, Hocqueloux, L, Prazuck, T., Gubavu, C, Sève, A, Maka, A, Boulard, C., Thomas, G, Cheret, A, Goujard, C, Quertainmont, Y, Teicher, E., Lerolle, N., Deradji, O, Barrail-Tran, A, Landman, R, Joly, V, Rioux, C., Lariven, S, gervais, a, Lescure, F., Matheron, S., Louni, F, Godard, C, Julia, Z, Chansombat, M, Rahli, D, Mackoumbou-Nkouka, C, Charpentier, c, Descamps, D., Peytavin, G., Yazdanpanah, Y., Tattevin, P., Revest, M., Souala, F., Baldeyrou, M., Patrat-Delon, S, Chapplain, J, Bénézit, F., Dupont, M., Poinot, M., MAILLARD, A, Pronier, C., Guennoun, C, Poisson-Vanier, M, Jovelin, T., Sinteff, J, Arvieux, C, Botelho-Nevers, E., Gagneux-Brunon, A., Frésard, A., Lucht, F., Ajana, F, Aïssi, E, Alcaraz, I, Baclet, V, Bocket, L, Boucher, A, Choisy, P, Huleux, T., Lafon-Desmurs, B., Meybeck, A, Pradier, M, Robineau, O, Viget, N, Valette, M., Hoen, B., Lamaury, I, Fabre, I, Curlier, E, Ouissa, R, Schepers, K, Herrmann-Storck, C, Dournon, N, Merrien, D, Perré, P., Guimard, T, Bollangier, O, Leautez, S, Morrier, M, Boglione-Kerrien, C., Picard, S., Tron, C., Nimubona, S., Gangneux, J.-P., Lalanne, S., Lemaître, F., Bellissant, E., Verdier, M.-C., Petitcollin, A., Centre d'Investigation Clinique [Rennes] (CIC), Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Pontchaillou [Rennes], Institut de recherche en santé, environnement et travail (Irset), Université d'Angers (UA)-Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-École des Hautes Études en Santé Publique [EHESP] (EHESP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Centre Hospitalier Universitaire de Nice (CHU Nice), Service des maladies infectieuses et tropicales [CHU Nantes], Centre hospitalier universitaire de Nantes (CHU Nantes), Epidémiologie et analyses en santé publique : risques, maladies chroniques et handicaps (LEASP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées, Immunité et Infection, Université Pierre et Marie Curie - Paris 6 (UPMC)-IFR113-Institut National de la Santé et de la Recherche Médicale (INSERM), Service de maladies infectieuses et tropicales [Nantes], Université de Nantes (UN)-Hôtel-Dieu-Centre hospitalier universitaire de Nantes (CHU Nantes), Centre Hospitalier Universitaire de Reims (CHU Reims), Service de Maladies Infectieuses et Tropicales [Hôpital de la Croix-Rousse - HCL], Hôpital de la Croix-Rousse [CHU - HCL], Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL), Institut de biologie et chimie des protéines [Lyon] (IBCP), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS), Hôpital Sainte-Marguerite [CHU - APHM] (Hôpitaux Sud ), DDSIS 76, Institut national de recherche et de sécurité (Vandoeuvre lès Nancy) (INRS ( Vandoeuvre lès Nancy)), Service des Maladies Infectieuses et Tropicales [Hôpital de la Conception] (SMIT), Assistance Publique - Hôpitaux de Marseille (APHM)-Hôpital de la Conception [CHU - APHM] (LA CONCEPTION ), Laboratoire de Physique et Chimie Quantique, Université Mouloud Mamerri, Pôle des Maladies Infectieuses et Tropicales Clinique et Biologique, Fédération de Bactériologie-Hygiène-Virologie, Assistance Publique - Hôpitaux de Marseille (APHM), Département de Physique Nucléaire (ex SPhN) (DPHN), Institut de Recherches sur les lois Fondamentales de l'Univers (IRFU), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Paris-Saclay-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Paris-Saclay, Génomique métabolique (UMR 8030), Genoscope - Centre national de séquençage [Evry] (GENOSCOPE), Direction de Recherche Fondamentale (CEA) (DRF (CEA)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Paris-Saclay-Direction de Recherche Fondamentale (CEA) (DRF (CEA)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Paris-Saclay-Université d'Évry-Val-d'Essonne (UEVE)-Centre National de la Recherche Scientifique (CNRS), Hospices Civils de Lyon (HCL), Hôpital Purpan [Toulouse], CHU Toulouse [Toulouse], Institut des Matériaux, de Microélectronique et des Nanosciences de Provence (IM2NP), Aix Marseille Université (AMU)-Université de Toulon (UTLN)-Centre National de la Recherche Scientifique (CNRS), Département Etude des Réacteurs (DER), CEA-Direction de l'Energie Nucléaire (CEA-DEN), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA), Hopital l'Archet, Centre d'Information et de Soins de I'Immunodéficience Humaine (CISIH). Hôpital l'Archet 1, Hôpital l'Archet, CHU Nice [Cimiez], Hôpital Cimiez [Nice] (CHU), Centre de résonance magnétique biologique et médicale (CRMBM), Aix Marseille Université (AMU)-Assistance Publique - Hôpitaux de Marseille (APHM)-Centre National de la Recherche Scientifique (CNRS), Centre Hospitalier Andrée Rosemon [Cayenne, Guyane Française], Centre d'Immunologie et de Maladies Infectieuses (CIMI), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), Hôtel-Dieu de Nantes, Service de virologie [CHU Nantes], Centre d'infectiologie Necker-Pasteur [CHU Necker], CHU Necker - Enfants Malades [AP-HP], Science et Technologie du Lait et de l'Oeuf (STLO), AGROCAMPUS OUEST-Institut National de la Recherche Agronomique (INRA), Institut des Sciences du Mouvement Etienne Jules Marey (ISM), Centre National de la Recherche Scientifique (CNRS)-Aix Marseille Université (AMU), Université Paris Descartes - Paris 5 (UPD5), Institut de Physique du Globe de Paris (IPGP), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut national des sciences de l'Univers (INSU - CNRS)-IPG PARIS-Université Paris Diderot - Paris 7 (UPD7)-Université de La Réunion (UR)-Centre National de la Recherche Scientifique (CNRS), Infection, Anti-microbiens, Modélisation, Evolution (IAME (UMR_S_1137 / U1137)), Université Paris 13 (UP13)-Université Paris Diderot - Paris 7 (UPD7)-Université Sorbonne Paris Cité (USPC)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service des maladies infectieuses [CHU Pitié-Salêtrière], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Pitié-Salpêtrière [APHP], Centre d'Investigation Clinique Antilles-Guyane (CIC - Antilles Guyane), Université des Antilles et de la Guyane (UAG)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pointe-à-Pitre/Abymes [Guadeloupe] -CHU de Fort de France-Centre Hospitalier Andrée Rosemon [Cayenne, Guyane Française], Système membranaires, photobiologie, stress et détoxication (SMPSD), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Centre National de la Recherche Scientifique (CNRS), Weill Cornell Medicine [Qatar], Institut Rayonnement Matière de Saclay (IRAMIS), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Paris-Saclay, Institut de pharmacologie moléculaire et cellulaire (IPMC), Université Nice Sophia Antipolis (UNS), Université Côte d'Azur (UCA)-Université Côte d'Azur (UCA)-Centre National de la Recherche Scientifique (CNRS), Centre de Recherche en Transplantation et Immunologie (U1064 Inserm - CRTI), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN), Laboratoire de Virologie [Strasbourg], GEOMA, Université de Vigo, Universidate de Vigo, Laboratoire Chrono-environnement - UFC (UMR 6249) (LCE), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Centre National de la Recherche Scientifique (CNRS)-Université de Franche-Comté (UFC), Laboratoire d'aérologie (LA), Centre National de la Recherche Scientifique (CNRS)-Observatoire Midi-Pyrénées (OMP), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées, Service des Maladies Infectieuses, Groupement Hospitalier Nord, Hospices Civils de Lyon, Lyon, France, parent, Pathogénie des Staphylocoques – Staphylococcal Pathogenesis, Centre International de Recherche en Infectiologie - UMR (CIRI), École normale supérieure - Lyon (ENS Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-École normale supérieure - Lyon (ENS Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Hosp Civils Lyon, Serv Malad Infect, Lyon, France, Equipe 15, Centre de Recherche en Cancérologie de Lyon (CRCL), Université de Lyon-Université de Lyon-Centre Léon Bérard [Lyon]-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre Léon Bérard [Lyon]-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Recherches Translationnelles sur le VIH et les maladies infectieuses (TransVIHMI), Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut de Recherche pour le Développement (IRD)-Université Montpellier 1 (UM1)-Université Cheikh Anta Diop [Dakar, Sénégal] (UCAD)-Universtié Yaoundé 1 [Cameroun]-Université de Montpellier (UM), Faculté des Mathématiques et des Sciences de la Matière, Université Kasdi Merbah Ouargla, Laboratoire de Géochimie Isotopique Environnementale (GIS) / Université de Nîmes (GIS), Université de Nîmes (UNIMES)-Centre National de la Recherche Scientifique (CNRS), CHU UCL Namur, Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM), Hôpital Bicêtre, Université Paris-Sud - Paris 11 (UP11)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpital Bicêtre, Centre de recherche en épidémiologie et santé des populations (CESP), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Université Paris-Sud - Paris 11 (UP11)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM), Service des maladies infectieuses et tropicales, Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-AP-HP - Hôpital Bichat - Claude Bernard [Paris]-Université Paris Diderot - Paris 7 (UPD7), AP-HP - Hôpital Bichat - Claude Bernard [Paris], Centre d'Etudes Lasers Intenses et Applications (CELIA), Université de Bordeaux (UB)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Centre National de la Recherche Scientifique (CNRS), Pharmacie de l'Hôpital Bichat, UMR CNRS 8179, Université de Lille, Sciences et Technologies-Centre National de la Recherche Scientifique (CNRS), Service des maladies infectieuses et réanimation médicale, Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Hôpital Pontchaillou, Les Hôpitaux Universitaires de Strasbourg (HUS), Service de pneumologie, Hôpital Pontchaillou-CHU Pontchaillou [Rennes], Unité des Rickettsies et pathogènes émergents (URPE), Unité de Recherche sur les Maladies Infectieuses et Tropicales Emergentes (URMITE), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR48, INSB-INSB-Centre National de la Recherche Scientifique (CNRS)-Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR48, INSB-INSB-Centre National de la Recherche Scientifique (CNRS), CHU Saint-Etienne, University Hospital and University Jean Monnet, Centre Hospitalier Tourcoing, CHU de Fort de France, Commissariat à l'énergie atomique et aux énergies alternatives (CEA), Centre Hospitalier Régional Universitaire [Besançon] (CHRU Besançon)-Hôpital Saint-Jacques, Laboratoire de Génie des Procédés et Matériaux - EA 4038 (LGPM), CentraleSupélec, Université de Rennes (UR)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM), and Université d'Angers (UA)-Université de Rennes (UR)-École des Hautes Études en Santé Publique [EHESP] (EHESP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique )

Subjects
0301 basic medicine, Male, Cancer Research, Posaconazole, Antifungal Agents, [SDV]Life Sciences [q-bio], Administration, Oral, Dat’AIDS cohort, Pharmacology, 030226 pharmacology & pharmacy, Gastroenterology, 0302 clinical medicine, MESH: Drug Monitoring, Medicine, Prospective Studies, Haematological malignancies, media_common, MESH: Aged, Hematology, MESH: Middle Aged, medicine.diagnostic_test, General Medicine, Middle Aged, [SDV.SP]Life Sciences [q-bio]/Pharmaceutical sciences, 90-90-90 target, 3. Good health, Posaconazole oral tablet, Oncology, Quartile, MESH: Young Adult, Hematologic Neoplasms, MESH: Administration, Oral, Female, Drug Monitoring, Antifungal prophylaxis, Safety, medicine.drug, Tablets, Drug, Adult, medicine.medical_specialty, media_common.quotation_subject, 030106 microbiology, Therapeutic drug monitoring, 03 medical and health sciences, Young Adult, Pharmacokinetics, Invasive fungal infections, Internal medicine, Pharmacovigilance, primary HIV infection, cascade of care, Humans, Aged, MESH: Humans, business.industry, MESH: Adult, TasP, Triazoles, MESH: Antifungal Agents, MESH: Prospective Studies, MESH: Male, MESH: Triazoles, MESH: Tablets, business, Liver function tests, MESH: Female, MESH: Hematologic Neoplasms
Abstract

International audience; PurposePosaconazole is a triazole antifungal widely used for prophylaxis of invasive fungal disease (IFI). Posaconazole tablets allow reaching higher plasma levels than the oral suspension, but safety data with this formulation in real life are scarce. This study aimed at evaluating the safety profile, the pharmacokinetic variability, and the concentration–toxicity relationship of posaconazole tablets in patients with haematological malignancies.MethodsSixty neutropenic patients treated with posaconazole tablets for prophylaxis of IFI were prospectively included in the study. Adverse drug reactions (ADR) were recorded and analyzed by the Regional Pharmacovigilance Centre to assess posaconazole implication. Blood samples were drawn once a week and plasma trough concentrations (C min) were assayed by LC–MS/MS. The rates of ADR by quartile of C min were compared.ResultsEighteen patients (30%) experienced at least one ADR attributed to posaconazole. Liver function test (LFT) abnormalities were encountered in 20% of patients and resulted in four (6.7%) treatment discontinuations. Posaconazole median (range) C min was 1.36 (< 0.1–3.44) µg/mL (inter-patient CV = 43.9%). During follow-up, 28.6% of patients had at least one concentration < 0.7 µg/mL, and 35.7% had at least one concentration > 2 µg/mL. Rates of ADR by quartile of C min were not different.ConclusionsPosaconazole was well tolerated; however, LFT abnormalities were frequent. ADR occurrence was not linked to posaconazole exposure. Because posaconazole concentrations were highly variable, TDM can be helpful to avoid underexposure to the drug and increase its efficacy in preventing IFI. Conversely, a large proportion of patients was overexposed and might have benefited of a dose reduction.

Published
2018
Full Text
View/download PDF

23. Long-term follow-up of HIV-infected patients on dolutegravir monotherapy.

Author

Tebano, G, Soulié, C, Schneider, L, Blanc, C, Agher, R, Seang, S, Valantin, M A, Palich, R, Tubiana, R, Peytavin, G, Marcelin, A G, Assoumou, L, and Katlama, C

Subjects
INTEGRASE inhibitors, HIV-positive persons, HIV, HIV infections, NUCLEOTIDE sequence, ANTI-HIV agents, PYRIDINE, HIV integrase inhibitors, HETEROCYCLIC compounds, VIRAL load, LONGITUDINAL method
Abstract

Background: In recent years, dolutegravir monotherapy has been explored as a drug-reduced regimen for HIV patients.Methods: This was a retrospective observational study, including patients virologically suppressed for ≥6 months, without previous virological failure (VF) under integrase inhibitors (INIs), who had been switched to dolutegravir monotherapy (50 mg/day). The primary aim was to report the proportion of VF at week 48 (W48) and week 96 (W96) of dolutegravir monotherapy. The evolution from baseline to W48 of residual viraemia on ultra-deep sequencing and HIV DNA was also evaluated.Results: Sixty-one patients were included. Prior to switching to dolutegravir monotherapy, they had a median (IQR) of 15.4 (6.5-19.9) years of antiretroviral exposure, 5.8 (3.2-10.3) years of viral suppression and 687 (461-848) CD4+ cells/mm3. They remained on dolutegravir monotherapy for a median (IQR) of 100 (29-148) weeks. Forty-two out of 61 patients (68.9%) reached W48 and 32 out of 61 patients (52.5%) reached W96. VF occurred in three patients, with the emergence of INI resistance. VF occurred before W24 and in patients pre-exposed to INIs. At W48, the probability of VF (Kaplan-Meier analysis) was 5.6% (95% CI = 1.8%-16.4%). The same result was obtained at W96. Detectable residual viraemia did not increase and median HIV DNA did not change significantly (2.4 log/106 cells at baseline and 2.3 log/106 cells at W48). Dolutegravir plasma concentration was above the IC90 in 41/41 samples, from 22 patients.Conclusions: Long-term follow-up showed a low risk of VF under dolutegravir monotherapy, in a selected population of patients with previous long-term virological suppression and low HIV reservoir. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

24. Une série de 21 cas d’infections causées par Trichophytonmentagrophytes génotype VII diagnostiquées chez des hommes ayant des relations sexuelles avec des hommes

Author

Jabet, A., Dellière, S., Seang, S., Barete, S., Nouchi, A., Brin, C., Bozonnat, A., Fekkar, A., Siguier, M., Chiarabini, T., Chasset, F., Canestri, A., Hennequin, C., Teboul, A., Hickman, G., Hamane, S., Benderdouche, M., Makhloufi, S., Piarroux, R., Normand, A.C., and Monsel, G.

Abstract

Depuis 2014, le génotype VII de Trichophyton mentagrophytes(TMVII) a été impliqué dans des cas de dermatophytoses sexuellement transmises diagnostiquées en Europe. Nous rapportons 21 cas d’infections par TMVII diagnostiquées entre janvier 2021 et mai 2023 dans quatre centres hospitaliers chez des hommes ayant des relations avec des hommes (HSH).

Published
2023
Full Text
View/download PDF

27. Darunavir/ritonavir monotherapy at a low dose (600/100 mg/day) in HIV-1-infected individuals with suppressed HIV viraemia.

Author

Peytavin, G., Seang, S., Schneider, L., Calin, R., Caby, F., Valantin, M. A., Tubiana, R., Katlama, C., Assoumou, L., Nguyen, T., Soulie, C., Marcelin, A. G., and Lê, M. P.

Subjects
*DARUNAVIR, *RITONAVIR, *VIREMIA, *HIV, *DRUG resistance, *DRUG resistance in microorganisms, *HIV infections, *VIRAL load, *TREATMENT effectiveness, *ANTI-HIV agents
Abstract

Background: Darunavir/ritonavir is a potent PI with a high genetic barrier and pharmacological robustness favourably investigated as monotherapy. Whether darunavir could be dose reduced in the context of monotherapy deserves investigation.Methods: Patients with HIV suppressed viraemia (plasma viral load <50 copies/mL for 12 months) under ART who had switched to darunavir/ritonavir monotherapy at 600/100 mg/day between 2013 and 2015 were included in this observational 48 week single-centre study. The primary outcome was the proportion of patients with virological success (defined as plasma viral load <50 copies/mL) at week 24. Secondary outcomes included treatment strategy success and resistance.Results: Thirty-one patients were included with the following baseline characteristics [median (IQR)]: age 52 years (47-57), CD4+ 649 cells/mm3 (463-813), ART duration 16.3 years (9.2-22.3), nadir CD4+ 195 cells/mm3 (144-261) and duration of HIV suppression 7.8 years (4.8-9.7). Prior to switch, ART consisted of PI monotherapy for 28 of 31 patients [darunavir/ritonavir 800/100 mg/day (n = 26), lopinavir/ritonavir (n = 1) and atazanavir/ritonavir (n = 1)] and a triple drug regimen for 3 of 31 patients. Within the 48 weeks of follow-up, no virological failure occurred and two patients discontinued 600/100 mg of darunavir/ritonavir due to side effects at week 16 and 40, leading to a virological suppression rate of 100% (95% CI = 89-100) at weeks 24 and 48. Strategy success rates were 96.8% (95% CI = 83.3-99.9) at week 24 and 93.5% (95% CI = 78.6-99.2) at week 48. Median (IQR) Ctrough values of 800/100 mg of darunavir/ritonavir and 600/100 mg of darunavir/ritonavir were 1537 ng/mL (1286-1724) and 1255 ng/mL (873-2161), respectively.Conclusions: A lower dose of darunavir/ritonavir used as monotherapy (600/100 mg/day) was highly effective in virologically suppressed HIV-infected patients. Further studies are needed to confirm these data. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

30. Prevalence and factors associated with symptom persistence: A prospective study of 429 mild COVID-19 outpatients

Author

Faycal, A., Ndoadoumgue, A.L., Sellem, B., Blanc, C., Dudoit, Y., Schneider, L., Tubiana, R., Valantin, M.-A., Seang, S., Palich, R., Bleibtreu, A., Monsel, G., Godefroy, N., Itani, O., Paccoud, O., Pourcher, V., Caumes, E., Ktorza, N., Chermak, A., Abdi, B., Assoumou, L., and Katlama, C.

Abstract

•The clinical presentation of patients with mild COVID-19 varies with age and gender.•Median time to recovery from mild COVID-19 was 27 days.•The probability of complete recovery was 56.3% at 1 month and 85.6% at 2 months.•Four independent factors were associated with symptom persistence at 1 month: female sex, age>40, ageusia, and a low cycle threshold.•Persistent symptoms were mainly asthenia, ageusia, anosmia, and dyspnea.

Published
2021
Full Text
View/download PDF

31. Assessement of Awareness of, Concerns and Attitudes Towards HIV-Related Court-Case Sentences in France in a Representative Sample of People Living with HIV (ANRS VESPA2 Survey)

Author

Marie Suzan-Monti, Bruno Spire, Antoine Vilotitch, Rosemary Dray-Spira, Patrick Yeni, Michel Celse, Baptiste Demoulin, Observatoire régional de la santé Provence-Alpes-Côte d'Azur [Marseille] (ORS PACA), Sciences Economiques et Sociales de la Santé & Traitement de l'Information Médicale (SESSTIM - U1252 INSERM - Aix Marseille Univ - UMR 259 IRD), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Conseil national du sida et des hépatites virales [Paris, France], Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), Université Paris Diderot - Paris 7 (UPD7), Centre de recherche en épidémiologie et santé des populations (CESP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris-Sud - Paris 11 (UP11)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), The VESPA2 survey was sponsored and funded by the French National Agency for Research on Aids and Viral Hepatitis (ANRS), Grant No. 2010-176., ANRS VESPA2 study group : Lert F, Spire B, Carrieri P, Dray-Spira R, Hamelin C, Lorente N, Préau M, Suzan-Monti M, Mora M, Le Strat Y, Cuzin L, Meyer L, Rojas-Castro D, Fischer H, Allègre T, Mours P, Riou JM, Sordage M, Chennebault JM, Fialaire P, Rabier V, Froidure M, Huguet D, Leduc D, Pichancourt G, Wajsbrot A, Bourdeaux C, Foltzer A, Hoen B, Hustache-Mathieu L, Abgrall S, Barruet R, Bouchaud O, Chabrol A, Mattioni S, Mechai F, Jeantils V, Bernard N, Bonnet F, Hessamfar M, Lacoste D, Malvy D, Mercié P, Morlat P, Paccalin F, Pertusa MC, Pistone T, Receveur MC, Vandenhende MA, Dupont C, Freire Maresca A, Leporrier J, Rouveix E, Dargere S, de la Blanchardière A, Martin A, Noyon V, Verdon R, Rogeaux O, Beytout J, Gourdon F, Laurichesse H, Meier F, Mortier E, Simonpoli AM, Cordier F, Delacroix I, Garrait V, Elharrar B, Dominguez S, Lascaux AS, Lelièvre JD, Levy Y, Melica G, Buisson M, Piroth L, Waldner A, Gruat N, Leprêtre A, de Truchis P, Le Du D, Melchior JC, Sehouane R, Troisvallets D, Blanc M, Boccon-Gibod I, Bosseray A, Brion JP, Durand F, Leclercq P, Marion F, Pavese P, Brottier-Mancini E, Faba L, Roncato-Saberan M, Bollengier-Stragier O, Esnault JL, Leautez-Nainville S, Perré P, Froguel E, Nguessan M, Simon P, Colardelle P, Doll J, Godin-Collet C, Roussin-Bretagne S, Delfraissy JF, Duracinsky M, Goujard C, Peretti D, Quertainmont Y, Marionneau J, Aissi E, Van Grunderbeeck N, Denes E, Ducroix-Roubertou S, Genet C, Weinbreck P, Augustin-Normand C, Boibieux A, Cotte L, Ferry T, Koffi J, Miailhes P, Perpoint T, Peyramond D, Schlienger I, Brunel JM, Carbonnel E, Chiarello P, Livrozet JM, Makhloufi D, Dhiver C, Husson H, Madrid A, Ravaux I, de Severac ML, Thierry Mieg M, Tomei C, Hakoun S, Moreau J, Mokhtari S, Soavi MJ, Faucher O, Ménard A, Orticoni M, Poizot-Martin I, Atoui N, Baillat V, Faucherre V, Favier C, Jacquet JM, Le Moing V, Makinson A, Mansouri R, Merle C, Elforzli N, Allavena C, Aubry O, Besnier M, Billaud E, Bonnet B, Bouchez S, Boutoille D, Brunet C, Feuillebois N, Lefebvre M, Morineau-Le Houssine P, Mounoury O, Point P, Raffi F, Reliquet V, Talarmin JP, Ceppi C, Cua E, Dellamonica P, De Salvador-Guillouet F, Durant J, Ferrando S, Mondain-Miton V, Perbost I, Pillet S, Prouvost-Keller B, Pradier C, Pugliese P, Rahelinirina V, Roger PM, Rosenthal E, Sanderson F, Hocqueloux L, Niang M, Prazuck T, Arsac P, Barrault-Anstett MF, Ahouanto M, Bouvet E, Castanedo G, Charlois-Ou C, Dia Kotuba A, Eid-Antoun Z, Jestin C, Jidar K, Joly V, Khuong-Josses MA, Landgraf N, Landman R, Lariven S, L'hériteau F, Machado M, Matheron S, Michard F, Morau G, Pahlavan G, Phung BC, Prévot MH, Rioux C, Yéni P, Bani-Sadr F, Calboreanu A, Chakvetadze E, Salmon D, Silbermann B, Batisse D, Beumont M, Castiel P, Derouineau J, Eliaszewicz M, Gonzalez G, Jayle D, Karmochkine M, Kousignian P, Pavie J, Pierre I, Weiss L, Badsi E, Bendenoun M, Cervoni J, Diemer M, Durel A, Rami A, Sellier P, Ait-Mohand H, Amirat N, Bonmarchand M, Bourdillon F, Breton G, Caby F, Grivois JP, Katlama C, Kirstetter M, Paris L, Pichon F, Roudière L, Schneider L, Samba MC, Seang S, Simon A, Stitou H, Tubiana R, Valantin MA, Bollens D, Bottero J, Bui E, Campa P, Fonquernie L, Fournier S, Girard PM, Goetschel A, Guyon HF, Lacombe K, Lallemand F, Lefebvre B, Maynard JL, Meyohas MC, Ouazene Z, Pacanowski J, Picard O, Raguin G, Roussard P, Tourneur M, Tredup J, Valin N, Balkan S, Clavel F, de Verdière NC, De Castro N, de Lastours V, Ferret S, Gallien S, Gérard L, Goguel J, Lafaurie M, Lascoux-Combe C, Molina JM, Oksenhendler E, Pintado C, Ponscarme D, Rozenbaum W, Scemla A, Bonnard P, Lassel L, Lebrette MG, Lyavanc T, Mariot P, Missonnier R, Ohayon M, Pialoux G, Treilhou MP, Vincensini JP, Gilquin J, Hadacek B, Nait-Ighil L, Nguyen TH, Sobel A, Viard JP, Zak Dit Zbar O, Aumaître H, Eden A, Ferreyra M, Lopez F, Medus M, Neuville S, Saada M, Blum L, Perfezou P, Arvieux C, Chapplain JM, Revest M, Souala F, Tattevin P, Bord S, Borsa-Lebas F, Caron F, Chapuzet C, Debab Y, Gueit I, Etienne M, Fartoukh C, Feltgen K, Joly C, Robaday-Voisin S, Suel P, Khuong MA, Krausse J, Poupard M, Tran Van G, Cazorla C, Daoud F, Fascia P, Frésard A, Guglielminotti C, Lucht F, Bernard-Henry C, Cheneau C, Lang JM, de Mautort E, Partisani M, Priester M, Rey D, Majerholc C, Zucman D, Assi A, Lafeuillade A, de Jaureguiberry JP, Gisserot O, Aquilina C, du Clary FP, Alvarez M, Chauveau M, Delobel P, Garipuy D, Labau E, Marchou B, Massip P, Mularczyk M, Obadia M, Ajana F, Allienne C, Baclet V, de la Tribonnière X, Huleux T, Melliez H, Meybeck A, Riff B, Valette M, Viget N, Bastides F, Bernard L, Gras G, Guadagnin P, May T, Rabaud C, Dos Santos A, Poinsignon Y, Derradji O, Escaut L, Teicher E, Vittecoq D, Bantsima J, Caraux-Paz P, Patey O., Lissalde, Claire, and Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Université Paris-Sud - Paris 11 (UP11)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)

Subjects
Adult, Male, medicine.medical_specialty, Adolescent, Social Psychology, Social stigma, Cross-sectional study, Social Stigma, Stigma (botany), HIV Infections, 03 medical and health sciences, Discrimination, Psychological, 0302 clinical medicine, Criminalization, 5. Gender equality, Criminal Law, Surveys and Questionnaires, medicine, Humans, 030212 general & internal medicine, 10. No inequality, Psychiatry, Prejudice (legal term), Transients and Migrants, Depressive Disorder, Major, Stereotyping, 030505 public health, Public health, Public Health, Environmental and Occupational Health, HIV, Awareness, Middle Aged, 16. Peace & justice, Health psychology, Cross-Sectional Studies, Sexual Partners, Infectious Diseases, Attitude, Socioeconomic Factors, [SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologie, Criminal law, Female, Key population, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, France, 0305 other medical science, Psychology, Prejudice
Abstract

International audience; Some of the 12 criminal trials and sentences in France for HIV transmission in 1998-2011 attracted substantial public attention , with a possible negative impact on people living with HIV (PLWH) through reinforced stigma and discrimination. This analysis aimed to characterize PLWH enrolled in the representative ANRS-VESPA2 survey, aware of and concerned about convictions for HIV transmission. Being a migrant from Sub-Saharan Africa, having difficult socioeconomic conditions, having unprotected sex with one's main partner and concealing one's HIV status were all factors statistically associated with concern about the sentences. Participants tempted to press charges against someone for infecting them were more likely to be younger, women, not living in a couple, unemployed, and to report a major depressive disorder. Concern about HIV-related criminal proceedings among the most vulnerable PLWH do not reflect the actual risk of prosecution they are exposed to. Resumen En Francia, algunos de los 12 juicios y sentencias relacionados con la contaminación del VIH en 1998-2011 suscitaron con-siderablemente el interés público. Esto pudo impactar negativamente las personas viviendo con VIH (PVVIH) aumentando su estigmatización y discriminación. Este análisis busca caracterizar las PVVIH, de la encuesta ANRS-VESPA2, informadas acerca de esos juicios e inquietos por la posibilidad de implicación en uno de ellos. Ser inmigrante subsahariano, las con-diciones socio-económicas desfavorables, las relaciones sexuales no protegidas con la pareja principal, y ocultar el VIH, están asociados a la posibilidad de ser implicados en un juicio. Por otro lado, aquellos que han intentado presentar cargos por contaminación del VIH fueron mayoritariamente jóvenes, mujeres, personas viviendo solas, desempleados, y personas en depresión. Los juicios por contaminación del VIH entre las PVVIH más vulnerables no reflejan el riesgo de acusación al que están expuestos.

Published
2018
Full Text
View/download PDF

32. No virological failure in patients living with HIV with past NNRTI resistance-associated mutations switched to doravirine-containing regimens.

Author

Abdi B, Saliba S, Wirden M, Faycal A, Cocherie T, Palich R, Schneider L, Seang S, Valantin MA, Pourcher V, Calvez V, Marcelin A, and Katlama C

Abstract

Background: Doravirine is licensed in patients living with HIV (PWH) harbouring no prior resistance to any NNRTIs. We aimed to evaluate in real life the efficacy of doravirine with prior NNRTI virological failure and NNRTI resistance-associated mutations (RAMs)., Methods: This observational study included PWH switched to a doravirine-containing regimen between 30 September 2019 and 1 May 2022, with an HIV-1 RNA of ≤50 copies/mL and past NNRTI-RAMs. The main outcome was the proportion of participants with virological failure at Week 48 and Week 96. Secondary outcomes evaluated the rate of viral suppression and transient virological blip, RAMs in the case of virological failure and side effects., Results: A total of 102 patients were analysed, mostly men (63%), with a median age of 59 years (IQR 51-63). The median time since HIV-1 diagnosis was 26 years (IQR 16-31), on ART for 22 years (IQR 14-26) and virally suppressed for 7 years (IQR 1-11).Of the patients analysed, 25/102 (25%) had documented historical RAMs to doravirine, 9/25 (36%) showing possible resistance and 16/25 (64%) showing major resistance. The resistance profile primarily (21/23) consisted of the K103N, Y181C and/or G190A/E reverse transcriptase substitutions. Median time since the last detection of NNRTI-RAMs was 12 years (5-17). Over 2 years follow-up, no virological failure occurred, neither at Week 48 (0/87; 0%) nor Week 96 (0/86; 0%)., Conclusions: This is the first real-world study to provide new insight about the use of doravirine-containing regimens as a treatment in long-term suppressed patients whose viruses harboured specific NNRTI-RAMs in their history., (© The Author(s) 2025. Published by Oxford University Press on behalf of British Society for Antimicrobial Chemotherapy. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.)

Published
2025
Full Text
View/download PDF

33. Clearance of archived integrase strand transfer inhibitors resistance mutations in people with virologically suppressed HIV infection.

Author

Abdi B, Palich R, Seang S, Fauchois A, Cocherie T, Faycal A, Sayon S, Teyssou E, Saliba S, Soulie C, Valantin MA, Pourcher V, Katlama C, Calvez V, Marcelin AG, and Wirden M

Abstract

Introduction: We assessed the kinetics of the clearance of integrase strand transfer inhibitors resistance mutations (INSTIs-RMs) and associated factors from people living with HIV (PWH) displaying suppressed viral replication after virological failure (VF) on an INSTI regimen., Patients and Methods: We included PWH with HIV-RNA viral loads ≤20 copies/mL for at least 5 years in whom INSTIs-RM had been identified at least once in a prior RNA resistance genotyping test. HIV DNAs were sequenced by Sanger sequencing (SS) and ultra-deep sequencing (UDS; detection threshold: 5%) every year over the preceding 5 years., Results: We included 39 PWH in the study. Most (95%) had experienced VF on a raltegravir-containing regimen. The past INSTIs-RMs were not detected in the peripheral blood mononuclear cells of 35 of the 39 (90%) PWH by SS at the end of follow-up. In a longitudinal analysis (2017-21) based on UDS, the previously detected INSTIs-RMs were not detected in 29 of the 35 (83%) PWH. In multivariable analysis, the duration of viral replication and the level of HIV-RNA during prior VF were significantly associated with the persistence of INSTIs-RM, with odds ratios of 1.05 per week of replication (95% CI, 1.00-1.11; P  = 0.024) and 8.26 per log 10 copies/mL (95% CI, 1.46-46.59; P  = 0.017)., Conclusions: We observed a clear trend towards the clearance of archived INSTIs-RM after a long period of virological control leading to changes in the resistance profile in cellular DNA, raising the possibility of studies assessing the recycling of INSTI classes even in the presence of a history of resistance., (© The Author(s) 2024. Published by Oxford University Press on behalf of British Society for Antimicrobial Chemotherapy.)

Published
2024
Full Text
View/download PDF

34. Bacterial Genomics for National Antimicrobial Resistance Surveillance in Cambodia.

Author

Yek C, Lon C, Chea S, Lay S, Oum MH, Tang G, Lon C, Pacheco AR, Drobish I, Stuehser R, Ly S, Sath R, Srouen M, Bin C, Chak C, Seang S, Srey V, Chhor B, Nhem S, Chiek S, Dork R, Dekker JP, Seng H, Krang S, Ly S, and Manning JE

Abstract

Background: Antimicrobial resistance (AMR) surveillance in low- and middle-income countries (LMICs) often relies on poorly resourced laboratory processes. Centralized sequencing was combined with cloud-based, open-source bioinformatics solutions for national AMR surveillance in Cambodia., Methods: Blood cultures growing gram-negative bacteria were collected at six Cambodian hospitals (January 2021 - October 2022). Isolates were obtained from pure plate growth and shotgun DNA sequencing performed in-country. Using public nucleotide and protein databases, reads were aligned for pathogen identification and AMR gene characterization. Multilocus sequence typing was performed on whole genome assemblies and haplotype clusters compared against published genomes., Findings: Genes associated with acquired resistance to fluoroquinolones were identified in 59%, TMP/SMX in 45%, and aminoglycosides in 52% of 715 isolates. Extended-spectrum beta-lactamase encoding genes were identified in 34% isolates, most commonly blaCTX-M-15, blaCTX-M-27, and blaCTX-M-55 in E. coli sequence types 131 and 1193. Carbapenemase genes were identified in 12% isolates, most commonly blaOXA-23, blaNDM-1, blaOXA-58 and blaOXA-66 in Acinetobacter species. Phylogenetic analysis revealed clonal strains of A. baumannii, representing suspected nosocomial outbreaks, and genetic clusters of quinolone-resistant typhoidal Salmonella and ESBL E. coli cases suggesting community transmission., Interpretation: With accessible sequencing platforms and bioinformatics solutions, bacterial genomics can supplement AMR surveillance in LMICs., Funding: Research was supported by the National Institute of Allergy and Infectious Diseases and the Bill and Melinda Gates Foundation [OPP1211806]., (Published by Oxford University Press on behalf of Infectious Diseases Society of America 2024.)

Published
2024
Full Text
View/download PDF

35. Effects of intermittent pneumatic compression devices interventions to prevent deep vein thrombosis in surgical patients: A systematic review and meta-analysis of randomized controlled trials.

Author

Kim NY, Ryu S, and Kim YH

Subjects
Humans, Venous Thrombosis prevention & control, Venous Thrombosis etiology, Intermittent Pneumatic Compression Devices, Randomized Controlled Trials as Topic
Abstract

This review aimed to determine the effectiveness of Intermittent Pneumatic Compression (IPC) intervention on Deep Vein Thrombosis (DVT) in surgical patients. An electronic database search was conducted with PubMed, OVID-MEDLINE, EMBASE, and CENTRAL, from September 22 to 28, 2023. Three researchers independently selected the studies, assessed their methodological quality, and extracted relevant data. We conducted a meta-analysis of the effect of IPC versus the control group and summarized the intervention results from the included studies. Of the 2,696 articles identified 16 randomized control trials met the inclusion criteria for review. IPC interventions significantly affected DVT prevention (OR = 0.81, 95% CI: 0.59-1.11). In the subgroup analysis, there was a significant pooled effect (OR = 0.41, 95% CI: 0.26-0.65]), when the comparison group was no prophylaxis group. However, when the comparison groups were the pharmacologic prophylaxis group ([OR = 1.32, 95% CI 0.78-2.21]) and IPC combined with the pharmacologic prophylaxis group (OR = 2.43, 95% CI: 0.99-5.96) did not affect DVT prevention. The pooled effects of Pulmonary Embolism (PE) (OR = 5.81, 95% CI: 1.25-26.91) were significant. IPC intervention showed a significant effect on bleeding prevention (OR = 0.17, 95% CI: 0.08-0.36) when compared to IPC combined with the pharmacologic groups. IPC intervention effectively prevented DVT, PE, and bleeding in surgical patients. Therefore, we propose that IPC intervention be applied to surgical patients to avoid DVT, pulmonary embolism, and bleeding in the surgical nursing field as scientific evidence suggests., Competing Interests: The authors have declared that no competing interests exist., (Copyright: © 2024 Kim et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.)

Published
2024
Full Text
View/download PDF

37. Case Report: Risk Factors Associated with Mortality in Adults with Burkholderia Pseudomallei Bacteremia: A Retrospective Case Series of Melioidosis in Cambodia.

Author

Pacheco AR, Chea S, Saunders H, Ly S, Sath R, Tim R, Lay S, Oum M, Tang G, Long L, Ly S, Seng H, Krang S, Chhuon C, Te V, Seang S, Lon C, Yek C, and Manning JE

Subjects
Humans, Cambodia epidemiology, Risk Factors, Male, Female, Retrospective Studies, Adult, Middle Aged, Aged, Young Adult, Melioidosis drug therapy, Melioidosis mortality, Melioidosis epidemiology, Melioidosis microbiology, Burkholderia pseudomallei isolation & purification, Burkholderia pseudomallei drug effects, Bacteremia mortality, Bacteremia drug therapy, Bacteremia microbiology, Anti-Bacterial Agents therapeutic use
Abstract

In resource-scarce settings, melioidosis is associated with up to 80% mortality. Studies of melioidosis in Cambodia report primarily on pediatric populations with localized infection; however, literature describing Cambodian adults with severe melioidosis is lacking. We present a case series of 35 adults with sequence-confirmed Burkholderia pseudomallei bacteremia presenting to a provincial referral hospital in rural Cambodia. More than 90% of the patients had diabetes, an important risk factor for developing melioidosis. Inappropriate antimicrobial therapy was significantly associated with lower odds of survival. Improved diagnostic testing and greater access to first-line antibiotics for acute melioidosis treatment present potential targets for intervention to reduce mortality associated with this disease in resource-limited settings.

Published
2024
Full Text
View/download PDF

38. Anti-inflammatory effects of the prostacyclin analogue iloprost in an in vitro model of inflamed human dental pulp cells.

Author

Wahyudi R, Seang S, Everts V, Osathanon T, and Limjeerajarus CN

Subjects
Humans, Interleukin-6, Dental Pulp metabolism, Interleukin-12 metabolism, Interleukin-12 pharmacology, RNA, Messenger metabolism, RNA, Messenger pharmacology, Anti-Inflammatory Agents pharmacology, Anti-Inflammatory Agents metabolism, Cells, Cultured, Lipopolysaccharides pharmacology, Lipopolysaccharides metabolism, Iloprost pharmacology, Iloprost metabolism, Epoprostenol metabolism, Epoprostenol pharmacology
Abstract

Iloprost's anti-inflammatory effects on human dental pulp stem cells (HDPCs) are currently unknown. We hypothesized that iloprost could downregulate the expression of inflammatory-related genes and protein in an inflamed HDPC in vitro model. To induce inflammation, the HDPCs were treated with a cocktail of interleukin-1 beta, interferon-gamma, and tumour necrosis alpha, at a ratio of 1:10:100. Iloprost (10 -6  M) was then added or not to the cultures. Interleukin-6 (IL-6) and interleukin-12 (IL-12) mRNA expression were assessed by real-time polymerase chain reaction. IL-6 protein expression was assessed by enzyme-linked immunosorbent assay. The results were analysed using one-way ANOVA or the Kruskal-Wallis test. The cytokine cocktail induced more robust IL-6 expression than LPS treatment. Iloprost slightly, yet significantly, downregulated IL-6 and IL-12 mRNA expression. These findings suggest that iloprost might be used as a beneficial component in vital pulp therapy., (© 2023 Australian Society of Endodontology Inc.)

Published
2023
Full Text
View/download PDF

39. Doravirine plus lamivudine two-drug regimen as maintenance antiretroviral therapy in people living with HIV: a French observational study.

Author

Perfezou P, Hall N, Duthe JC, Abdi B, Seang S, Arvieux C, Lamaury I, Menard A, Marcelin AG, Katlama C, and Palich R

Subjects
Adult, Male, Humans, Middle Aged, Female, Lamivudine adverse effects, Anti-Retroviral Agents therapeutic use, CD4 Lymphocyte Count, RNA therapeutic use, Viral Load, HIV Infections drug therapy, Anti-HIV Agents adverse effects
Abstract

Background: Two-drug regimens based on integrase strand transfer inhibitors (INSTIs) and boosted PIs have entered recommended ART. However, INSTIs and boosted PIs may not be suitable for all patients. We aimed to report our experience with doravirine/lamivudine as maintenance therapy in people living with HIV (PLWH) followed in French HIV settings., Methods: This observational study enrolled all adults who initiated doravirine/lamivudine between 1 September 2019 and 31 October 2021, in French HIV centres participating in the Dat'AIDS cohort. The primary outcome was the rate of virological success (plasma HIV-RNA < 50 copies/mL) at Week (W)48. Secondary outcomes included: rate of treatment discontinuation for non-virological reasons, evolution of CD4 count and CD4/CD8 ratio over follow-up., Results: Fifty patients were included, with 34 (68%) men; median age: 58 years (IQR 51-62), ART duration: 20 years (13-23), duration of virological suppression: 14 years (8-19), CD4 count: 784 cells/mm3 (636-889). Prior to switching, all had plasma HIV-RNA < 50 copies/mL. All but three were naive to doravirine, and 36 (72%) came from a three-drug regimen. Median follow-up was 79 weeks (IQR 60-96). Virological success rate at W48 was 98.0% (95% CI 89.4-99.9). One virological failure occurred at W18 (HIV-RNA = 101 copies/mL) in a patient who briefly discontinued doravirine/lamivudine due to intense nightmares; there was no resistance at baseline and no resistance emergence. There were three strategy discontinuations for adverse events (digestive disorders: n = 2; insomnia: n = 1). There was no significant change in CD4/CD8 ratio, while CD4 T cell count significantly increased., Conclusions: These preliminary findings suggest that doravirine/lamivudine regimens can maintain high levels of viral suppression in highly ART-experienced PLWH with long-term viral suppression, and good CD4+ T cell count., (© The Author(s) 2023. Published by Oxford University Press on behalf of British Society for Antimicrobial Chemotherapy. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.)

Published
2023
Full Text
View/download PDF

40. Sexually Transmitted Trichophyton mentagrophytes Genotype VII Infection among Men Who Have Sex with Men.

Author

Jabet A, Dellière S, Seang S, Chermak A, Schneider L, Chiarabini T, Teboul A, Hickman G, Bozonnat A, Brin C, Favier M, Tamzali Y, Chasset F, Barete S, Hamane S, Benderdouche M, Moreno-Sabater A, Dannaoui E, Hennequin C, Fekkar A, Piarroux R, Normand AC, and Monsel G

Subjects
Humans, Male, Female, Coitus, Homosexuality, Male, Trichophyton genetics, Genotype, Antifungal Agents therapeutic use, Arthrodermataceae, Tinea diagnosis, Tinea epidemiology, Tinea drug therapy, Sexual and Gender Minorities, Sexually Transmitted Diseases drug therapy
Abstract

Transmission of dermatophytes, especially Trichophyton mentagrophytes genotype VII, during sexual intercourse has been recently reported. We report 13 such cases in France. All patients were male; 12 were men who have sex with men. Our findings suggest sexual transmission of this pathogen within a specific population, men who have sex with men.

Published
2023
Full Text
View/download PDF

42. Intermittent Bictegravir/Emtricitabine/Tenofovir Alafenamide Treatment Maintains High Level of Viral Suppression in Virally Suppressed People Living with HIV.

Author

Sellem B, Abdi B, Lê M, Tubiana R, Valantin MA, Seang S, Schneider L, Fayçal A, Peytavin G, Soulié C, Marcelin AG, Katlama C, Pourcher V, and Palich R

Abstract

In this observational study, we aimed to evaluate whether bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) administered 5 or 4 days a week is able to maintain viral suppression in people living with HIV (PLHIV). We enrolled 85 patients who initiated intermittent B/F/TAF between 28 November 2018 and 30 July 2020: median (IQR) age 52 years (46-59), duration of virological suppression 9 years (3-13), CD4 633/mm 3 (461-781). Median follow-up was 101 weeks (82-111). The virological success rate (no virological failure [VF]: confirmed plasma viral load [pVL] ≥ 50 copies/mL, or single pVL ≥ 200 copies/mL, or ≥50 copies/mL with ART change) was 100% (95%CI 95.8-100) and the strategy success rate (pVL < 50 copies/mL with no ART regimen change) was 92.9% (95%CI 85.3-97.4) at W48. Two VF occurred at W49 and W70, in 2 patients self-reporting poor compliance. No resistance mutation emerged at time of VF. Eight patients presented strategy discontinuation for adverse events. There was no significant change in the CD4 count, residual viraemia rate, neither body weight during follow-up, but a slight increase in CD4/CD8 ratio ( p = 0.02). In conclusion, our findings suggest that B/F/TAF administered 5 or 4 days a week could maintain the control of HIV replication in virologically suppressed PLHIV while reducing cumulative exposition of ART.

Published
2023
Full Text
View/download PDF

44. Birth Country Influences the Choice of Antiretroviral Therapy in HIV-Infected Individuals: Experience From a French HIV Centre.

Author

Palich R, Agher R, Wetshikoy DJ, Cuzin L, Seang S, Soulie C, Tubiana R, Valantin MA, Schneider L, Pourcher V, Marcelin AG, Assoumou L, and Katlama C

Subjects
Female, Humans, CD4 Lymphocyte Count, France epidemiology, RNA therapeutic use, Viral Load, Africa South of the Sahara, Male, Anti-HIV Agents therapeutic use, HIV Infections drug therapy, HIV Infections epidemiology, HIV Integrase Inhibitors therapeutic use
Abstract

Objectives: To assess whether antiretroviral therapy (ART) prescriptions differ between naive and virally suppressed HIV patients born in France (PBFs) and in Sub-Saharan Africa (PBSSAs)., Setting: Observational single-center study., Methods: We included all PBFs and PBSSAs who entered into care at Pitié-Salpêtrière Hospital, Paris, France, from 01/01/2000 to 31/12/2018, with plasma HIV-RNA>200 copies/mL. We first compared the initial ART in naive PBFs and PBSSAs. Second, we compared the last-prescribed ART (including drug-reduced ART: daily 2-drug regimens, daily 1-drug regimens and intermittent 3-drug regimens) in virally suppressed PBFs and PBSSAs, by focusing on patients in care in 2018 with HIV-RNA <50 copies for at least 24 months. A univariable and multivariable logistic regression model was used to assess the impact of geographical origin on ART prescriptions., Results: A total of 1944 naive patients were included (915 PBSSAs and 1029 PBFs). PBSSAs were more frequently women, hepatitis B coinfected, with a lower pretherapeutic CD4 T-cell count, and most had tuberculosis at HIV diagnosis. After adjustment for confounders, PBSSAs were more likely to receive a first-line protease inhibitor-based regimen (OR 1.61, 95% CI: 1.31 to 1.98), and less likely to receive an integrase inhibitor-based regimen (OR 0.61, 95% CI: 0.42 to 0.88). Of the 968 virally suppressed patients (431 PBSSAs and 537 PBFs), PBSSAs were less likely to receive drug-reduced ART, including 2-drug regimens and intermittent three-drug regimens (OR 0.48, 95% CI: 0.36 to 0.65)., Conclusions: Differences in ART prescriptions between PBSSAs and PBFs were not only explained by different clinical and virologic situations. Personal motivations of doctors in choosing ART according to country of birth need to be explored., Competing Interests: R.P., L.C., S.S., C.S., R.T., M.A.V., L.S., V.P., and C.K. have received travel grants and honoraria from Gilead, ViiV Healthcare, and Merck. AGM has received travel and research grants and honoraria from Gilead, ViiV Healthcare, Theratechnologies and Merck. The remaining authors have no conflicts of interest to disclose., (Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.)

Published
2023
Full Text
View/download PDF

45. Viral loads in clinical samples of men with monkeypox virus infection: a French case series.

Author

Palich R, Burrel S, Monsel G, Nouchi A, Bleibtreu A, Seang S, Bérot V, Brin C, Gavaud A, Wakim Y, Godefroy N, Fayçal A, Tamzali Y, Grunemwald T, Ohayon M, Todesco E, Leducq V, Marot S, Calvez V, Marcelin AG, and Pourcher V

Subjects
Male, Humans, Adult, Monkeypox virus, Viral Load, Homosexuality, Male, Mpox, Monkeypox epidemiology, Mpox, Monkeypox diagnosis, Sexual and Gender Minorities, HIV Infections epidemiology
Abstract

Background: Monkeypox virus (MPXV) is currently spreading among men who have sex with men, outside of sub-Saharan Africa, and close contact during sex seems to be one of the key pathways of viral transmission in the current outbreak. Our aim was to describe the distribution of MPXV in the human body, as it might play a role in its dissemination through sexual contact., Methods: The study population in this case series consisted of patients with confirmed MPXV infection attending the Pitié-Salpêtrière Hospital (Paris, France), who had been sampled from multiple anatomical sites, including skin, anus, throat, blood, urine, and semen, at diagnosis and 2 weeks later. We compared the proportion of positive samples and MPXV viral loads (given as PCR cycle thresholds [Ct]) between anatomical sites, and between day 0 (D0) and D14., Findings: Overall, 356 samples were collected between May 20 and June 13, 2022, from 50 men with a median age of 34 years (IQR 29-40). 22 (44%) of the 50 men were classified as HIV-negative on day (D)0, and 22 (44%) were living with HIV. At D0, MPXV detection was more frequent from skin (44 [88%] of 50), anus (30 [71%] of 42), and throat (36 [77%] of 47) than from blood (13 [29%] of 45), urine (nine [22%] of 41), or semen (13 [54%] of 24). Viral loads were significantly higher from skin lesions (Ct 19·8) and anal samples (Ct 20·9) than from throat (Ct 27·2), blood (Ct 32·8), urine (31·1), or semen samples (Ct 27·8). When analysing the 107 samples taken from 24 patients at D14, the proportion of positive samples strongly decreased between D0 and D14 at all sites: skin (four [22%] of 18), anus (two [9%] of 22), throat (none of 21), blood (one [5%] of 21), urine (none of 14), and semen (two [9%] of 11)., Interpretation: These data contribute to a better understanding of how the virus might spread between sexual partners over a relatively short period of time. High MPXV viral loads from skin and mucosa, including genital and anal sites, suggest that transmission most likely occurs through direct body contact rather than through the respiratory route or contact with body fluids, which should help to refine the prevention messages delivered to individuals most exposed to the virus., Funding: None., Competing Interests: Declaration of interests We declare no competing interests., (Copyright © 2023 Elsevier Ltd. All rights reserved.)

Published
2023
Full Text
View/download PDF

46. A Case of Perforated Cholecystitis into a Parastomal Hernia.

Author

Seang S, Hort A, Gosal PKS, and Richardson M

Abstract

Introduction: Parastomal hernia is a common complication following an enterostomy. Gallbladder herniation into parastomal hernia is rare and may become symptomatic and inflamed and very rarely can lead to gallbladder perforation. We present the first case of gallbladder perforation inside a parastomal hernia with a unique skin change. Case Description . In this report, an 87-year-old female with a history of previous open cystectomy and ileal conduit formation, presented with right upper quadrant pain and worsening parastomal swelling. A computed tomography scan showed a parastomal herniation of the gallbladder, cholelithiasis, and possible early acute cholecystitis. Within 12 hours of admission, bile staining skin changes developed around her urostomy site which raised our suspicion of a perforated gallbladder. Biliary peritonitis was confirmed on laparoscopy the same day. We proceeded with an open midline cholecystectomy without hernia repair. The patient was well at her last follow-up. Discussion . A literature review found 14 published cases of incarcerated gallbladder hernia. This uncommon condition mainly affects elderly females. Ten cases were managed operatively, and four cases were managed nonoperatively, with good outcomes. Currently, no consensus on treatment guidelines exists. In a frail elderly patient, a nonoperative approach may be suitable. Operative management was indicated in this case due to clinical concerns of perforation due to developing skin changes. This cutaneous sign has not been previously documented in the literature., Conclusion: While rare, the gallbladder can herniate and become incarcerated inside a parastomal hernia. Bile staining of the skin should raise clinical suspicion of perforation. Management options depend on patient and pathology factors and can be nonoperative or operative, with or without hernia repair., Competing Interests: The authors declare no conflicts of interest., (Copyright © 2022 Sereibanndith Seang et al.)

Published
2022
Full Text
View/download PDF

47. Laparoscopic choledochotomy and choledochoduodenostomy for the management of persistent common bile duct stones.

Author

Harbhajan Singh TS, Seang S, Roy SP, and Majid A

Abstract

Choledochotomy and choledochoduodenostomy were commonly used technique in the early twentieth century to extract bile duct stones. Endoscopic retrograde cholangiopancreatography and sphincterotomy revolutionised the scenario and is currently the preferred first-line option for managing choledocholithiasis. However, in certain circumstances, where endoscopic retrograde cholangiopancreatography fails, choledochotomy and choledochoduodenostomy are the only available options. We present the case of an 86-year-old female with a background of multiple previous presentations with biliary sepsis and ascending cholangitis requiring multiple endoscopic retrograde cholangiopancreatographies that failed to remove all stones in the common bile duct. She underwent a laparoscopic choledochotomy and choledochoduodenostomy that successfully resolved her common bile duct obstruction. Laparoscopic choledochotomy and choledochoduodenostomy reduce the length of hospital stay and help to minimise complications associated with open surgery., Competing Interests: Declaration of conflicting interests: The author(s) declared no potential conflicts of interest with respect to the research, authorship and/or publication of this article., (© The Author(s) 2022.)

Published
2022
Full Text
View/download PDF

49. Effect of Delirium Prevention Program on Delirium Occurrence and the Length of Intensive Care Unit (ICU) Stay: A Systematic Review and Meta-Analysis.

Author

Ryu S, Kim YH, and Kim NY

Abstract

Background: ICU patients typically experience diverse kinds of distress factors, which make them vulnerable to delirium thereby resulting in a higher rate of delirium occurrence. We aimed to review systematically current states of preventive nursing intervention in ICUs, and to analyze delirium occurrence and the length of ICU stay to provide suggestions for the preventive nursing practice in ICU., Methods: Data collection was done with literature search databases including PubMed, Ovid-MEDLINE, EMBASE, CINAHL, KMbase, KoreaMed, Korean Studies Information Service System (KISS), Korea Institute of Science and Technology Information (KiSTi), Research Information Service System (RISS) and with hand searching, from Apr 20 to May 10, 2020. Two researchers independently selected research literature, and three researchers summarized and identified related variables based on data extraction methods., Results: Overall, 236 articles identified, 11 articles met the inclusion criteria for review. The systematic review of the contents of preventive nursing intervention other than drug administration rendered the four types of intervention. The Peto odds ratio (OR) of the rate of delirium occurrence appeared as 0.29 (95% Confidence Interval (CI)=0.20∼0.43) which was statistically significant ( Z =6.23, P <.01) in both group. The magnitude of the effect for the length of ICU stay demonstrated insignificant values, Mean difference ( MD ) -0.23 (95% CI =-0.51∼0.05) ( Z =1.60, P =.11)., Conclusion: For management of delirium among ICU patients, multi-component intervention packages, suitable for care setting in ICUs, need to be taken into account for the preparation of nursing intervention for prevention of delirium applicable to nursing practices., Competing Interests: Conflict of interest The authors declare that there is no conflict of interest., (Copyright © 2022 Ryu et al. Published by Tehran University of Medical Sciences.)

Published
2022
Full Text
View/download PDF

50. High SARS-CoV-2 seroprevalence in HIV patients originating from sub-Saharan Africa in the Ile-de-France area: Seroprevalence of SARS-CoV-2 in HIV patients.

Author

Abdi B, Ndoadoumgue AL, Djebara S, Zafilaza K, Palich R, Marot S, Schneider L, Wirden M, Seang S, Dudoit Y, Teyssou E, Tubiana R, Soulie C, Valantin MA, Katlama C, Calvez V, Assoumou L, Marcelin AG, and Pourcher V

Subjects
Africa South of the Sahara epidemiology, Antibodies, Viral, Humans, SARS-CoV-2, Seroepidemiologic Studies, COVID-19, HIV Infections complications, HIV Infections epidemiology
Abstract

Competing Interests: Declaration of Competing Interest None to declare.

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results